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ABSTRACT 
 
For any cell within a multicellular organism, a multitude of environmental signals 
influence cell fate.  The context and timing of these often redundant and overlapping 
signaling cascades govern whether a cell will differentiate, reproduce or die.  Some of 
these signaling networks form checkpoints that sense and respond to the needs of the 
individual cell.  In cancer, often one or more of these signals is missing or mutated which 
results in uncontrolled cell growth, usually to the detriment of the organism.  
Understanding the signaling events that normally control cell proliferation and death is 
important for controlling and eliminating cancerous cells.  Microtubule targeting drugs 
have been used to disrupt mitotic progression and cause cell death in cancer cells because 
of their typically high proliferation rates.  However, these drugs kill normal dividing cells 
and damage healthy tissues.  Therefore, there have been great efforts to find selective 
ways to target cancerous cells without harming normal cells.   
 One of the major regulators of genomic stability in cells is p53.  Mutations or 
gene deletions of p53 are present in over half of all cancers.  Many studies have 
demonstrated that p53-deficient cells are uniquely vulnerable to depletion of a 
microtubule regulator protein called stathmin. Stathmin depletion slows proliferation via 
a mitotic entry delay (including results presented in Chapter 2) and increases cell death in 
p53-deficient cells.  Research presented in this dissertation addresses the mechanisms by 
which stathmin loss delays mitotic entry and triggers cell death.    
 In order to know why cells are slow to enter mitosis we investigated the activity 
of the enzymes that govern mitotic entry. We previously found stathmin-depleted cells 
have decreased active CDK1.  The level of active CDC25, which removes CDK1 
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inhibition, was also reduced in these cells.  However, none of the upstream regulators that 
might inhibit CDC25 activation were changed upon stathmin depletion.  Therefore, we 
hypothesized that loss of stathmin directly affects the core enzymes in the mitotic entry 
complex.  We found that stathmin depletion decreases activation of Aurora A kinase 
(AURKA) and Polo-like Kinase 1 (PLK1), two key enzymes of the mitotic entry 
feedback loop that control CDK1 activation kinetics.  
 Since stathmin depletion delays mitotic entry and causes apoptotic cell death, we 
hypothesized that the cell cycle delay and cell death were linked.  We found that inducing 
a mitotic entry delay with the use of enzyme inhibitors to AURKA and PLK1 was 
sufficient to trigger cell death but only in cells lacking functional p53.  To understand the 
mechanism of the cell death in these cells we looked for activation of initiator caspases 8 
and 9, the primary drivers of apoptosis.  We found caspase 8 activation in both stathmin-
depleted and mitotic entry-delayed cells.  Additionally, we were able to rescue viability 
of these cells by inhibiting caspase 8 activity indicating that  cell death occurs via a 
caspase 8 dependent pathway.  CDK1 is known to inhibit a number of caspases including 
caspase 8 via a protective phosphorylation. We found that phosphorylation of caspase 8 
at Serine 387 was decreased in stathmin-depleted cells, suggesting an increased 
sensitivity of caspase 8 to activation.   
   In order to understand the role of p53 for survival in stathmin depletion we 
hypothesized that p53 may regulate a caspase 8 inhibitor.  We found the level of cFLIP, a 
major inhibitor of caspase 8, to be decreased in the absence of p53, consistent with the 
observations of others.  We were able to rescue viability of stathmin-depleted cells by 
restoring cFLIP level.  Therefore we concluded that in the absence of p53, decreased 
 3 
cFLIP levels lower the threshold for caspase 8 activation.  The absence of stathmin and 
p53 results in loss of two inhibitors of caspase 8.  The sum of inhibition may be sufficient 
to either stochastically trigger cell death or increase susceptibility to other death signals.  
Regardless of the mechanism, modulating stathmin or disrupting mitotic entry directly 
represents a potential selective and potent means of targeting p53 deficient cancers.   
 4 
Chapter 1: Introduction 
 Control of Cell Fate 
 For multicellular organisms, a full grown adult is comprised of trillions of cells 
that invariably arose from a single cell.  For each cell, whether it is a zygote or part of a 
larger tissue or organ system, a complex array of signals determine its fate.  The choice 
for each cell is to differentiate, reproduce or die, a decision regulated by myriad inputs 
that are continuously read and interpreted.  Disturbances in the system of checks and 
balances results in inappropriate cell growth or death and can lead to degenerative 
disorders or cancer. Cancer cells missing these checks and balances are able to out 
compete their neighboring cells, outgrow their environmental boundaries and destroy 
normal tissue function. All of the signaling layers including feedback mechanisms and 
pathway cross-talk that govern cell fate remain to be fully understood. Research results 
contained in this dissertation describe novel layers of regulation that control timing of 
cell division and cell fate.   
 
Cell Division Cycle 
 All proliferating cells go through the cell division cycle, during which they 
increase in volume and make more cell components and duplicate their genetic material.  
A new daughter cell exits mitosis into G1 phase where it awaits growth factor and 
mitogen signals, which will trigger growth of the cell and commit the cell to divide. In 
the absence of DNA damage or other stress, the cell will then duplicate its genome only 
once, as well as its centrosomes, the microtubule organizing centers, in S phase.  After 
successful duplication, the cell prepares for division by confirming that all components 
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are undamaged, of appropriate number and at the right intracellular location. These 
checks include proper fragmentation of the Golgi apparatus, release of focal adhesions, 
re-localization of key signaling molecules as well as the integrity of the DNA.  If all is 
within a normal range, the cell then prepares for mitosis where the genetic material, now 
condensed chromatin, as well as cytoplasmic components, organelles and various 
membranes segregate between the two forming cells.  The transition between G2 and 
mitosis is highly regulated and involves multiple and redundant safeguard mechanisms to 
ensure that cell division occurs correctly and at the appropriate time.   
 The preparation for mitosis is principally an enzymatic process occurring at 
distinct subcellular locations.  During G2, cyclin B protein level gradually rise and 
associate with cyclin dependent kinase 1, CDK1, at centrosomes to form mitotic cyclin 
dependent kinase complexes.  The association of the CDK with its cyclin causes the T-
loop in the kinase, which would otherwise block kinase activity, to change conformation.  
Phosphorylation by CAK (CDK Activating Kinase- CDK7 complexes with cyclin H) on 
Threonine 160 further extends the T-loop resulting in a fully active kinase.  However, 
prior to the activating phosphorylation by CAK, another kinase, Wee1, phosphorylates at 
two sites, threonine 14 and tyrosine15, which inhibit full kinase activity.  The result is a 
cyclin dependent kinase that is primed for activation.  
 However, like all enzymatic processes within the cell, there are rapid state 
changes, which result in short-lived active cyclin CDK1 without inhibitory 
phosphorylations present.  Active CDK1 complexes can activate Polo-like kinase 1 
(PLK-1) and Aurora A kinase (AURKA), which phosphorylate (activate) CDC25, a dual 
specificity phosphatase, to remove inhibitory phosphorylations from other cyclin 
 6 
B/CDK1 complexes.  In addition, CDK1 also directly phosphorylates Wee 1 kinase and 
inhibits its activity.  These two phosphorylation events occur gradually until some critical 
active CDK1 concentration is reached that gives rise to a rapid and nearly complete 
hyperphosphorylation of both Wee1 and CDC25.  The result of this hypersensitivity of 
Wee1 and CDC25 is an all or nothing requirement for mitotic entry, the mitotic switch 
(Trunnel 2011).   
 Following this switch, a rapid amplification of CDK1 activity results in 
phosphorylation of target proteins that drive a number of cellular events.  Endoplasmic 
reticulum and Golgi membranes fragment to facilitate subsequent segregation of the 
organelles to new daughters.  Phosphorylation of histones and condensins drive 
chromatin condensation.  Phosphorylated nuclear lamins and nuclear envelope proteins 
promote the disassembly of the nuclear envelope, which is necessary for the association 
of chromatin with the spindle poles.  In addition, microtubule associated proteins, MAPs, 
are also phosphorylated to facilitate reorganization of the microtubule array into the 
mitotic spindle (Kline-Smith 2004). 
 
Microtubules and the Cell Cycle 
 Along with the accumulation of cellular signals, necessary changes occur in the 
microtubule cytoskeleton in order to allow the formation of the mitotic spindles, which 
will separate the chromatin and assist in cytokinesis. Microtubules are polar polymers 
consisting of alternating subunits of alpha and beta tubulin proteins that assemble from 
soluble heterodimer pools in the cytoplasm. Both alpha and beta tubulin have GTP in 
binding pockets but only the site on beta tubulin is accessible for hydrolysis.   These 
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protofilaments, usually a set of thirteen, form hollow tubes, lending to their name, 
microtubules. Microtubule assembly most often begins at a microtubule organizing 
complex (MTOC), typically a centrosome, where several molecules of gamma tubulin 
with other proteins form a ring complex.  This complex referred to as gamma-Tubulin 
Ring Complex, gamma- TURC, nucleates microtubule growth by providing both a point 
of nucleation for subunit addition as well a template for the appropriate pitch of the helix. 
Microtubule assembly is driven by the concentration of free subunits of tubulin dimers.  
Subunit addition takes place primarily at plus ends since in vertebrate cells the minus 
ends are anchored to the MTOC.  Initially a new microtubule forms a sheet-like lattice, 
which rolls up into a cylinder once it has grown enough.  As new subunits are added, the 
GTP in beta tubulin already incorporated into the polymer hydrolyzes, a process that is 
actually stimulated by the longitudinally adjacent alpha-tubulin.  GDP-beta tubulin has a 
curved formation that opposes the stable straight structure of the cylinder.  The remaining 
GTP-beta tubulin at the plus ends prevents disassembly of the polymer by holding the 
protofilaments in a straight conformation and is referred to as the GTP cap.  Hydrolysis 
of these GTP-tubulins leads to loss of the GTP cap, an event called catastrophe, allowing 
the protofilaments, which make up the microtubule to peel outward from the central axis 
of the cylinder.  Tubulin subunits are lost and the microtubule shortens until complete 
disassembly or a new GTP-cap can form, an event defined as rescue. The fate of the caps 
and the longevity of each microtubule can also be affected by microtubule associated 
proteins, MAPs, which can either promote or decrease stability of the cylinder. 
 Within many interphase cells, there are typically two populations of microtubules, 
a population that is stable and a larger one that exhibits this dynamic instability.   The 
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dynamic microtubules are able to search the intracellular space and interact with 
peripheral proteins that link them to other cellular structures such as actin filaments as 
well as to position the centrosome within the cell (Wade 2009, Akhmanova 2008). 
  The traditional view of microtubule dynamics holds that changes in dynamics are 
driven by cellular signals originating both inside and outside of the cell.  Most research 
has focused on the effect signaling molecules have on the cytoskeleton; however, there 
are also many examples of how changes within the microtubule array can result in 
changes in activation or locations of signaling molecules. For example, Rho guanine 
exchange factor, HEF1, binds microtubules but upon nocodazole treatment, it becomes 
unbound and can activate Rho (Chang 2008). This example and others demonstrate how 
signaling can arise in an inside-out fashion. The microtubule state can relay cellular 
signals by controlling the location and availability of key signaling molecules.  
 At mitotic entry the characteristics and number of microtubules changes 
drastically.  This change is brought on by changes to the microtubule associated proteins 
that are regulated by CDK1.  The long, stable microtubules that persist during interphase 
must be disassembled rapidly in order to form the mitotic spindle.  
 
Microtubules at Mitotic Entry 
 The microtubule transition between interphase and mitosis occurs at the end of 
prophase at nuclear envelope breakdown.  Work by the Borisy lab group characterized 
the key events that occurred in the microtubule array at this point of the cell cycle.  The 
two possibilities for rearranging the microtubule skeleton were that the network was 
reorganized, keeping the majority of polymer together like the established mitosis/G1 
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transition or that the microtubules were first disassembled and then rebuilt from 
individual subunits.  Using fluorescence redistribution after photoactivation to measure 
MT turnover, they discovered that there was a steep drop in polymer near the time of 
nuclear envelope breakdown (NEB) and a corresponding increase in soluble tubulin.  
There is a shift in microtubule arrangement, the long cytoplasmic microtubules that 
spanned the radius of the cell disappear and in their place are short microtubules 
distributed out of the centrosome early in prometaphase, or the forming spindle.  By 
metaphase, the majority of microtubules originate in the spindle and are oriented toward 
the aligned chromatids; few astral microtubules also exist.  In order for a new interphase 
array to form once mitosis is complete, there is no disassembly of the mitotic array, as 
indicated by no drop in polymer level, the tubulin is reorganized among the existing 
microtubules (Zhai 1996).  
 Further work by the Wadsworth lab characterized the complete reorganization of 
microtubules at NEB by looking at individual microtubules. They found that the 
depolymerization that takes place is due to an increase in the incidence of catastrophe, a 
decrease in pausing and a decrease in rescue frequency.  They divided collapse of the 
array into two mechanisms.  The first is the increase in dynamic instability of individual 
microtubules.  The second mechanism arose from observations of short microtubule 
bundles moving along individual microtubules towards the centrosome.  They determined 
that cytoplasmic dynein was predominantly responsible for the minus end directed 
motion of these bundles.  It is likely that both of these mechanisms are necessary for 
complete remodeling of the microtubule array to form a spindle (Rusan 2002).  
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Stathmin and Mitotic Entry 
 Work by a number of labs revealed a requirement for a microtubule regulatory 
protein, stathmin, in proliferation and survival of certain cancer cells. Initial studies using 
stathmin-targeted ribozymes or survivin-promoter driven siRNA expression vector, 
identified that loss of stathmin leads to an accumulation of G2/M cells, loss of 
clonogenicity and increased apoptosis in a prostate cancer cell line and slowed 
proliferation and increased cell death in cancerous but not in non-cancerous cell lines 
(Mistry 2005, Zhang 2006).  Small interfering RNA targeting stathmin also increased 
sensitivity to treatment with chemotherapeutic taxanes, making stathmin an attractive 
candidate for cancer therapies (Alli 2002, Wang, 2007). Stathmin transcription and 
subsequent protein level are negatively regulated in part by p53 (Murphy 1999).  Work 
by the Hait lab attempting to restore some function to p53 deficient cells by depleting 
stathmin discovered that stathmin loss in p53 deficient cells caused slowed proliferation 
and apoptotic cell death (Alli 2007). Alli et al. suggested that loss or mutation of p53 
specifically in combination with stathmin depletion gave rise to two unique phenotypes, a 
G2/M arrest and apoptosis.  If this model were correct it would suggest that loss of 
stathmin, perhaps via microtubule changes, and loss of p53 signaling are read and 
summed by individual cells to negatively influence cell fate.  
 
Stathmin and Cell Fate 
 Stathmin acts as a microtubule destabilizer by both sequestering free tubulin and 
promoting catastrophe of existing microtubules (Howell 1999, Larsson 1999, Belmont 
and Mitchison 1996).  Phosphorylation of stathmin at four serine sites renders stathmin 
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functionally off with respect to tubulin, a modification that occurs during mitosis and in 
response to various stresses such as heat shock, changes in cellular calcium, and through  
ASK1, p38 and JNK signaling (Beretta  1995, Larsson 1999, Gradin 1997, Hu 2010, 
Mizumura 2006).  It was initially proposed that stathmin, from the Greek “stathmos” 
meaning “station” acts as a cellular relay to regulate cellular proliferation, differentiation 
and function (Sobel 1991).  Therefore stathmin’s name seems particularly fitting given 
what we now know about stathmin’s role in cell proliferation and survival, which is 
presented in Chapter’s 2 and 3 of this dissertation.   
 Previous research from the Cassimeris Lab revealed that stathmin depletion leads 
to slowed proliferation caused by a mitotic entry delay (Carney 2012) and that interaction 
of stathmin and tubulin are necessary for timely mitotic entry (Carney unpublished).  The 
cell death observed in stathmin-depleted cells appeared to be apoptosis, based on 
observed cell morphology, presence of cleaved PARP and involvement of caspase 3 
activity and was confirmed to be dependent on the absence of p53 as restoration of the 
p53 rescued cells from death (Carney 2010, 2012).  As described in Chapter 2 of this 
dissertation, stathmin depletion delays mitotic entry via decreased activation of mitotic 
kinases AURKA and PLK1, which slows kinetics of CDK1 activation.  Decreased CDK1 
activity at mitotic entry as is found with stathmin depletion is sufficient to induce cell 
death in cells missing p53, demonstrated in Chapter 3 of this dissertation. 
 
Programmed Cell Death 
 When it comes to cells there are many ways to die including: necrosis, entosis, 
mitotic catastrophe and autophagy, perhaps the most studied however, is apoptosis, a 
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form of programmed cell death.  Apoptosis is characterized by distinct morphological 
changes and enzymatic events involving signal cascades by caspases.  Cells undergoing 
programmed cell death typically undergo blebbing to form apoptotic bodies that in vivo 
will be engulfed by phagocytic cells such as macrophages.  The signal that initiates 
apoptotic cell death can originate from within the cell or from the external environment.  
Loss of mitochondrial outer membrane integrity (MOMP) allows release of cytochrome 
c, which facilitates oligomerization of APAF, which recruits and dimerizes/activates 
caspase 9.  Activation of caspase 9 to form the apoptosome triggers cleavage and 
activation of executioner caspases 3 and 7, leading to cleavage of other substrates that 
lead to the chemical and physical changes associated with apoptosis (Green 2005). These 
changes include nuclear fragmentation, exposure of phosphatidylserine on the outer 
plasma membrane and formation of microvesicle or apoptotic bodies.   
 Apoptosis can also be initiated from external signals and may or may not include 
MOMP.  Extracellular death ligands such as Fas ligand or TNFα bind to death receptors 
and induce oligomerization and recruitment of adaptor proteins such as FADD or 
TRADD respectively.  Death domain association facilitates binding of procaspase 8 and 
autolytic cleavage to produce active caspase 8.  Caspase 3 and 7 are activated by caspase 
8 and apoptosis proceeds by the same pathway as described with caspase 9 activation 
(Wang 2008).  New findings have also uncovered unconventional roles for caspase 8 
activity both in cell death and survival that can be independent of death signaling (Day 
2008). In the absence of a caspase activator, removal of apoptotic inhibitors such as 
occurs in genotoxic stress can be sufficient to induce caspase 8 dependent cell death 
(Tenev 2011).  Additionally, the autoprocessing of caspase 8 is also inhibited by 
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phosphorylation by CDK1/cyclin B and ERK, which elevate the threshold necessary for a 
cell's response to extrinsic death signals. (Matthess 2010).   
 In addition to caspase 8, CDK1/cyclin B also regulates and inhibits activation of 
Caspase 1, 2, 4, 5, and 9 (Andersen 2009, Harley 2010).  Clearly cells at mitosis are 
strongly protected against cell death perhaps due to their inherent vulnerability during 
this portion of the cell cycle.  During division cells undergo loss of attachment and 
mitochondrial fission that may otherwise trigger death from anoikis response or 
accidental cytochrome c release (Andersen 2009).  As described in Chapter 3, caspase 8 
phosphorylation at Serine 387 by CDK1 is significantly reduced in both stathmin 
depletion and direct CDK1 inhibition, translating to a lowered threshold for caspase 8 
activation in these cells.  
 
cFLIP and p53 Dependent Death  
 Cellular FLICE Protein, cFLIP, is an anti-apoptotic regulator that binds to FADD 
and/or caspase 8, 10 (Safa 2012).  Caspase 8 activation and cleavage occurs in two steps.  
Upon homodimerization, caspase 8 autoproteolysis produces two cleavage products, a 
p43 and p10 subunit from each procaspase 8.  Each p43 subunit is further cleaved to 
produce a p18 subunit that complexes with p10 subunit. Two p18 and p10 subunits 
oligomerize to form a fully active caspase 8 complex.  At certain cellular concentrations, 
cFLIP promotes initial autocatalytic processing to p43 from procaspase 8 but inhibits 
further cleavage required for fully active caspase 8, p18/p10 complex formation (Budd 
2006, Krueger 2001). However, cells are sensitive to changing levels of cFLIP protein 
and at low or high concentrations cFLIP can promote death by dimerizing with caspase 8 
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resulting in full caspase activation (Chang 2002). cFLIP’s specific role in caspase 8 
regulation and ultimate cell fate decisions is complicated and still incompletely described. 
However, siRNA to cFLIP sensitizes cells to other apoptotic triggers such as TRAIL 
signaling (Safa 2012, Galligan 2005). 
 Intracellular levels of cFLIP are regulated in part by p53, which has been 
suggested to control cFLIP transcription and/or degradation (Bartke 2010, Fukazawa 
2001).  Mutations and deletions of p53 therefore correlate with changes in cFLIP levels 
that increase susceptibility of cells to caspase 8 dependent death.  As described in 
Chapter 3 of this dissertation, in the absence of p53, cFLIP levels are decreased which in 
conjunction with CDK1 inhibition is sufficient to trigger cell death.  Restoring cFLIP 
levels in stathmin-depleted cells restores cell viability indicating a role for cFLIP in 
inhibition of caspase 8 activation.  The combinatorial effect of reduced caspase 8 
phosphorylation and loss of cFLIP inhibition sums to alter the probability of apoptosis.   
 Cell to cell variability in total levels of caspases, cFLIP and other apoptotic 
regulators as well as the concentration of membrane localized death receptors likely 
accounts for the unpredictability in death timing.  For each cell, these ratios are likely 
unique which accounts for the unpredictability of time of death observed in stathmin-
depleted or CDK1 inhibited cells.  As described in Chapter 3, activation of a cell death 
pathway is stochastic, occurring not during the mitotic entry delay but rather hours to 
days following the initial delay.  The only time cell death is rarely observed is during 
mitosis as almost all cell death occurs at some point during interphase.  These cells die at 
variable times following mitotic exit suggesting that death is not triggered by a specific 
cell cycle event. 
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 These findings suggest that targeting stathmin or mitotic entry are attractive 
therapeutic strategies for p53 null and loss of function mutations as they cause no or 
minimal mitotic disruption and selectively favor death in p53 deficient cells.  AURKA or 
PLK1 inhibitors are currently in clinical phase I and II clinical trials.  Either inhibitor at 
established effective doses yields a distinct mitotic arrest with abnormal spindles, which 
leads to mitotic slippage and cell death or aneuploidy (Steegmaier 2007, Lu 2010, Hoar 
2007). However, combination therapy of lower concentrations AURKA and PLK1 
inhibitors has the potential to only effect mitotic entry.  Thus proper titration of combined 
inhibitors may allow mitosis to proceed normally avoiding adverse effects on normal 
dividing cells as well as aneuploidy.   Alternatively, small molecule inhibitors or viral 
mediated knockdown of stathmin in tumor cells may offer greater selectivity and success 
as prospective therapies, particularly in combination with low doses of other effective 
compounds such as taxanes (Miceli 2013, Mistry 2007, Alli 2002).  Research described 
in this dissertation suggests interrupting mitotic entry as a novel therapeutic approach for 
the selective targeting of the majority of cancer cells.     
  
 16 
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Chapter 2:  
 
Abstract  
 
Depletion of stathmin, a microtubule destabilizer, slows cell proliferation and delays cells 
during G2. We find that mitotic entry is delayed in these cells through reduced activation 
of CDC25 and its upstream activators, Aurora A and Plk1. Reduced activation of both 
Aurora A and Plk1 is likely responsible for the cell cycle delay since treatment with 
chemical inhibitors to both enzymes, but not to either kinase alone, delayed mitotic entry 
with timing similar to that in stathmin-depleted cells. Aurora A localization to the 
centrosome required an intact microtubule cytoskeleton and stathmin depletion spread its 
localization beyond that of γ-Tb at the centrosome, indicating a microtubule-dependent 
regulation of Aurora A activation. Plk1 was inhibited by excess stathmin, detected using 
in vitro assays and in cells overexpressing stathmin-CFP. Recruitment of Plk1 to the 
centrosome was delayed in stathmin-depleted cells; this delayed localization was 
independent of microtubules. Depolymerizing microtubules with nocodazole abrogates 
the stathmin-depletion induced cell cycle delay (Carney et al., 2012) and restored Plk1 
activity to near normal levels, demonstrating that microtubules also contribute to Plk1 
activation. These data demonstrate that stathmin regulates mitotic entry, partially via 
microtubules, to control localization and activation of both Aurora A and Plk1.  
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Introduction 
 
 Several current cancer therapies are aimed at halting cell division and most do so 
by disrupting the microtubule (MT) cytoskeleton (Jordan and Wilson, 2004). However, 
these therapies also damage normal tissue and therefore have widespread toxicity. More 
selective approaches are being developed that target MT accessory proteins and/or 
exploit possible synergies between new and current therapies (Jordan and Kamath, 2007; 
Mitra et al., 2011; Leinung et al., 2012).  
 The microtubule regulatory protein, stathmin, has been implicated in survival of 
certain cancer cell lines, including those missing a functional p53 protein. Depleting cells 
of stathmin leads to slowed growth (Zhang et al., 2006; Chen et al., 2007; Wang et al., 
2007; Carney and Cassimeris, 2010; Carney et al., 2012), an accumulation of cells with 
4N DNA content (Alli et al., 2002; Mistry et al., 2005) and an increased occurrence of 
apoptosis (Alli et al., 2007; Belletti et al., 2011). However, the mechanisms slowing 
proliferation and causing cell death have not been defined but at least in some cases 
depend on loss of both p53 and stathmin (Carney and Cassimeris, 2010). Interpretations 
by others suggest that stathmin depletion leads to a G2/M (Johnsen et al., 2000; Polager 
et al., 2003) or mitotic block (Alli et al., 2007) however, stathmin is phosphorylated 
during mitosis at four serine sites by CDKs and other protein kinases and is functionally 
off with respect to MT regulation (Larsson et al., 1997; Holmfeldt et al., 2009). We 
previously demonstrated that stathmin depletion in Hela cells leads to an accumulation of 
cells in the G2 cell cycle stage (Carney and Cassimeris, 2010) and an increase in the 
interphase duration without a change in the timing of mitosis (Carney et al., 2012). Based 
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on these data we hypothesized that stathmin-depleted cancer cells were slowed in G2 
prior to mitotic entry.  
The commitment to enter mitosis relies on integration of various environmental 
and cellular inputs that either drive or slow progression into mitosis by regulating the 
activation state of cyclin B/CDK1. Beginning in early G2, cyclin B level rises in the 
cytosol and by mid-G2 cyclin B accumulates on centrosomes in complex with CDK1, 
forming what is historically known as the maturation-promoting factor (Linqvist et al., 
2009). The cyclinB-CDK1 complex is both negatively and positively regulated by 
phosphorylations by Wee1 kinase at threonine 14 and tyrosine 15 and by CAK1 at 
threonine 160, respectively. CDC25 B/C phosphatases remove the inhibitory 
phosphorylation allowing for full kinase activity. Accumulation of active CDC25, a key 
component of the “mitotic trigger”, occurs rapidly (Trunnel et al., 2011). The events 
leading to maximal activation of CDK1 are highly regulated. Positive and negative 
feedback pathways ensure that the commitment to enter mitosis, including nuclear 
envelope breakdown, only occurs when all checkpoints have been satisfied (Reider, 
2011). DNA damage, defects in Golgi fragmentation, perturbations of proteins 
functioning in cell adhesion and activation of cellular stress pathways such as those 
involving p38 can arrest cells in G2 until the stressor or damage is addressed (Ando et al., 
2007; Persico et al., 2010; Molli et al., 2010; Reinhardt et al., 2010; Michal et al., 2012). 
Most of these inhibitory signals directly or indirectly converge at the level of CDK1 via 
CDC25 phosphatase activation at the centrosome (Perry and Kornbluth, 2007). 
The centrosome serves as the major localization site for enzymes controlling 
mitotic entry in addition to its role as the microtubule-organizing center of the cell 
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(Kramer et al., 2004). There is evidence to support overlap of these processes, in 
particular mitotic enzymes such as Plk1 and Aurora A Kinase (AURKA) regulate MT 
nucleation and assembly at centrosomes (Kang et al., 2006; Katayama et al., 2008; Xu 
and Dai, 2011; Toya et al., 2011). Therefore, it is likely that MTs may in turn also affect 
activity and/or localization of these molecules.  
The MT cytoskeleton also functions in signal transduction, acting either through 
MT dynamics or through sequestration of MT interacting proteins (Gunderson and Cook, 
1999; Reider and Cole, 2000; Ezratty et al., 2005; Efimov and Kaverina, 2009). Stathmin 
binds tubulin dimers and/or MTs to control partitioning of tubulin between the soluble 
and polymer pools (Holmfeldt et al., 2007; Sellin et al., 2008). Stathmin also regulates 
MT nucleation at centrosomes and therefore sets MT number (Howell et al., 1999; 
Ringhoff and Cassimeris 2009).  
From our previous results showing that cells depleted of stathmin were delayed in 
the G2 phase of the cell cycle, we concluded that stathmin was necessary for timely 
progression through G2 and entry into mitosis (Carney and Cassimeris, 2010). 
Additionally, we found that the delay induced by stathmin depletion could be abrogated 
by treatment with nocodazole to depolymerize MTs, suggesting that stathmin’s role is 
carried out via microtubules, a new function for the MT cytoskeleton in mitotic entry 
(Carney et al., 2012). In order to determine the cause of delayed mitotic entry induced by 
stathmin depletion, we examined the signaling pathways that converge on cyclin-
B/CDK1 activation. We found that levels of active AURKA and Plk1 were significantly 
decreased in stathmin-depleted prophase cells and that a G2 delay could be induced by 
treatment with chemical inhibitors to not one, but to both AURKA and Plk1 enzymes. 
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These data support a model where decreased stathmin level delays mitotic entry by 
inhibiting both of these enzymes. To test whether AURKA and Plk1 were regulated by 
stathmin via MTs, we treated stathmin-depleted cells with nocodazole and were able to 
partially restore activity of Plk1, but not of AURKA. We discovered that AURKA 
localization at the centrosome and subsequent activation was abolished by nocodazole 
treatment, indicating a role for MTs in AURKA recruitment to the centrosome. Plk1 
recruitment to centrosomes was delayed in stathmin-depleted cells, and this delayed 
recruitment was independent of MTs. Collectively these data indicate that stathmin, at 
least partially through its effects on MTs, regulates mitotic entry by controlling activation 
of both AURKA and Plk1, a novel role for MTs in cell cycle progression.  
 
Results: 
Common G2 checkpoint pathways are not activated by stathmin depletion  
 To determine why loss of stathmin delays mitotic entry, we first asked whether 
stathmin depletion activated upstream checkpoint pathways that ultimately reduce CDK1 
activation. SiRNA transfection reduced stathmin protein level to approximately 25% of 
that in cells transfected with a non-targeting siRNA. Protein depletion was detected 
within 24 hours and knockdown was maintained beyond 48 hours post transfection 
(Figure 1 B; note that an shRNA targeting a second region in stathmin produced the same 
knockdown and delay in G2, Carney and Cassimeris, 2010). We had previously shown 
that stathmin depletion increased the population of cells staining positive for 
CDK1(Y15P) (inhibitory phosphorylation) indicating that cyclinB-CDK1 complexes 
were present, but less active in these cells (Carney and Cassimeris, 2010). The inhibitory 
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phosphorylation is removed by CDC25 phosphatases (Figure 2.1, A). We found that 
active CDC25, marked by phosphorylation at T48, a modification necessary for full 
phosphatase activity (Izumi and Maller, 1993) was reduced in stathmin-depleted cells 
(Figure 2.2). Several G2 checkpoint pathways converge at the level of CDC25's, where 
activation of a checkpoint inhibits CDC25 activation. We examined several G2 
checkpoint proteins for modifications that could lead to decreased CDC25 activation. We 
did not find evidence to support activation of these upstream pathways, including: p38 
(via phosphorylation on T180 or Y182), DNA damage responsive pathways (via CHK1 
phosphorylation on S317) or Wee 1 kinase (predominantly regulated by protein level). 
Additionally, cyclin B protein levels accumulated normally in these cells (data not 
shown) indicating that the delayed mitotic entry was not due to disruption of an earlier 
event. Because we saw diminished activation of CDC25 phosphatase, without activation 
of several upstream pathways that respond to signals and inhibit CDC25, we next 
examined the activation of AURKA and Plk1, two enzymes able to activate CDC25. 
 
Stathmin depletion reduces active Aurora A kinase on centrosomes 
 Since AURKA plays a major role in activation of CDC25 and is part of a positive 
feedback loop including Plk1 and CDC25 that fully activates CDK1/cyclin B (Dutertre et 
al., 2004; Figure 2.1, A), we examined the levels of active AURKA in stathmin-depleted 
Hela cells.  In late G2, AURKA is recruited to the centrosome where it is activated 
following its dimerization, which facilitates autophosphorylation at T288 (Eyers et al., 
2003; Joukov et al., 2010). Phosphorylation of T288 is typically used as a convenient 
marker of active AURKA (Ohashi et al,. 2006).  We found that the amount of active 
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AURKA kinase at the centrosomes of Hela cells was reduced to ~ 50% of control levels 
as determined by quantitative immunofluorescence using an antibody specific for 
AURKA T288P (Figure 2.1, E and F).  This reduced activation was not due to a 
reduction in total AURKA protein level (Figure 2.1, C and D). 
 Our previous data indicated that loss of both stathmin and p53 was necessary for 
slowed cell proliferation (Alli et al., 2007; Carney and Cassimeris, 2010), so we also 
asked whether p53 protein level contributed to the decline in active AURKA, or whether 
the inhibition was strictly dependent on stathmin. Hela cells normally lack detectable 
levels of p53 because the HPV viral protein E6, present in these cells, targets p53 for 
proteasomal degradation (Scheffner et al., 1990). Depletion of viral protein E6 in Hela 
cells allowed p53 to accumulate (Koivusalo et al., 2005, Figure 2.3).  Restoring p53 did 
not change the levels of either total or active AURKA at centrosomes (Figure 2.1, C, E 
and F).  We also found that regardless of p53 level, stathmin depletion was sufficient to 
decrease AURKA T288P levels, indicating that stathmin, and not p53, controls activation 
of AURKA at the centrosome (Figure 2.1, E and F) in these cells. 
 
Inhibiting AURKA with specific kinase inhibitor S 1451 is not sufficient to slow mitotic 
entry  
 We next asked whether partial inhibition of AURKA was sufficient to delay 
mitotic entry by treatment with a chemical inhibitor. Using a specific inhibitor to 
AURKA, S 1451, which blocks phosphorylation of AURKA on T288 (Yuan et al., 2012), 
we treated Hela cells with 300 nM S 1451 and measured the phosphorylation states of 
AURKA and Plk1. The inhibitor concentration was chosen based on published IC50 
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values (Aliagas-Martin et al., 2009) and confirmed in cell proliferation assays (our 
unpublished data). We found that the level of AURKA T288P at centrosomes in S 1451 
treated Hela cells was reduced to 50% of DMSO-treated cells (Figure 2.4, A), which 
matches the reduction in active AURKA measured after stathmin depletion (see Figure 
2.1 E and F). We found that treatment with S 1451 did not change the level of active Plk1 
(T210P) (data not shown), which was surprising since AURKA activity is necessary for 
Plk1 activation (Seki et al., 2008). It is possible that the residual 50% active AURKA is 
sufficient to activate Plk1.  
 To ask whether AURKA inhibition was sufficient to delay progression through 
interphase, we followed individual cells by phase contrast microscopy, collecting images 
at 5 minute intervals for up to 72 hours. Interphase and mitotic durations were measured 
as described in Methods. Treatment of Hela cells with 300nM S 1451 did not increase 
interphase duration but rather shortened interphase by approximately 30 minutes 
compared to DMSO treated controls (Figure 2.4, B).  Mitotic duration in S 1451 treated 
cells was significantly increased by an average of 1 hour (Figure 2.4, C) as others have 
reported (Hoar et al., 2007). These chemical inhibitor studies indicate that stathmin 
depletion cannot delay mitotic entry only by partial inhibition of AURKA. 
 
Stathmin depletion leads to decreased levels of active Plk1 within the nucleus 
 Plk1 is necessary for G2 checkpoint maintenance and recovery from checkpoint 
activation through its phosphorylation (activation) of CDC25 (Tsvetkov and Stern, 2004; 
Macurek et al., 2008).  We hypothesized that the cell cycle delay induced by stathmin 
depletion also involved reduced activation of Plk1. We found that total levels of Plk1 do 
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not change with stathmin depletion as measured by western blot (Figure 2.5, A) or 
immunofluorescence (Figure 2.5, B). However, active Plk1 within the nucleus, as 
measured by quantitative immunofluorescence of phosphorylation on T210 (Lowery et 
al., 2005), was reduced in stathmin-depleted cells to 30% of control levels (Figure 2.5, C 
and D), and confirmed by western blot (Figure 2.5, E). We observed Plk1 (T210P) 
predominantly within the nucleus, consistent with a previous report (Lee et al., 2008). 
We did not consistently observe phosphorylated Plk1 (T210P) on centrosomes, unlike 
what some have observed (Kishi et al., 2009), therefore we confined our measurements to 
nuclear-localized, active Plk1. It is likely that centrosome-localized phospho-Plk1 was 
not detected by the antibody used here since we clearly observed Plk1 on centrosomes 
with an antibody recognizing the protein independent of its phosphorylation state, as 
described below.   
 Consistent with previous reports, we confirmed that p53 restoration in Hela cells 
reduced total Plk1 protein level (Figure 2.5, A) concomitant with p53’s role in Plk1 
transcription inhibition (McKenzie et al., 2010). Restoring p53 by depletion of E6 also 
reduced the level of active Plk1 on chromatin (T210P level; Figure 2.5 C and D). The 
decreased activation of Plk1 in these cells is likely due, at least in part, to reduced Plk1 
expression. Taken together, these data indicate that p53 controls Plk1 expression while 
stathmin depletion reduces Plk1 activation.  
 Since stathmin depletion led to a reduction in both active AURKA and Plk1, it is 
possible that either partial inhibition of Plk1, or the combined partial inhibition of both 
AURKA and Plk1 was responsible for the delayed mitotic entry observed in stathmin-
depleted cells. We next used chemical inhibitors to test these possibilities.  
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Inhibiting Plk1 with inhibitor BI 2536 is not sufficient to slow mitotic entry 
 If the G2 delay induced by stathmin depletion were due to reduced Plk1 
activation, then we would expect that chemical inhibition of Plk1 would delay mitotic 
entry. To inhibit Plk1 we used a specific inhibitor, BI 2536, at a concentration based on 
published IC50 values (Steegmaier et al., 2007) and confirmed in cell proliferation assays 
(our unpublished data). We treated Hela cells with 0.8 nM BI 2536 and measured cell 
cycle times. Inhibition of Plk1 with BI 2536 increased interphase duration by 
approximately 2.5 hours (Figure 2.6, A) and increased mitotic duration by about eleven 
minutes (Figure 2.6, B). Although the increased time in mitosis was modest, the 
lengthening of mitosis was statistically significant compared to DMSO-treated controls. 
The Plk1 inhibitor used here blocks the enzyme's ATP binding pocket but does not 
prevent phosphorylation at T210 (Scutt et al., 2009), typically used as a marker of 
enzyme activation. Therefore we could not use T210P as a measure of Plk1 inhibition. 
 Although Plk1-inhibited cells took longer to progress through interphase, this 
delay could reflect either a delay in mitotic entry or earlier in the cell cycle since Plk1 
was recently reported to function in late G1 by regulating firing of replication origins 
(Song et al., 2012). To test whether the small interphase delay observed in BI 2536 
treated cells was due to delayed mitotic entry, we synchronized cells with a double 
thymidine block and released them into media containing 0.8nM BI 2536. Mitotic index 
was determined at 2-hour intervals for 12 hours after release. We found that Hela cells 
synchronized at the G1/S border and released into Plk1 inhibitor, BI 2536, entered 
mitosis with normal timing compared to control cells released into DMSO (Figure 2.6, 
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C). These data demonstrate that Plk1 inhibition alone is not sufficient to delay mitotic 
entry. 
Simultaneous Inhibition of both AURKA and Plk1 delays mitotic entry 
 Inhibition of either AURKA or Plk1 alone did not mimic the G2 delay induced by 
stathmin depletion and we therefore hypothesized that partial inhibition of both enzymes 
was necessary to produce a cell cycle delay. We treated asynchronously growing Hela 
cells with a combination of 300 nM S 1451 and 0.8 nM BI 2536 to inhibit both AURKA 
and Plk1 kinases. Cells treated with both inhibitors were delayed significantly in mitosis 
and many died by apoptosis (detected by changes in cell morphology) and as such we 
were not able to calculate interphase durations in these cells. To avoid possible effects of 
a prolonged preceding mitosis and loss of cell number due to death, we synchronized 
cells at the G1/S border using a double thymidine block, released cells into media 
containing both 300nM S 1451 and 0.8nM BI 2536 and determined mitotic index at 2 
hour intervals for 12 hours. The combination of inhibitors delayed the peak of mitotic 
entry by 4 hours; shifting from 8 hours to 12 hours post release compared to DMSO-
treated control cells (Figure 2.6, C). This delay is similar to the 4.6 hour delay measured 
in stathmin-depleted cells (Carney et al., 2012). We then wanted to confirm that stathmin 
depletion delays cells by partial inhibition of AURKA and PLK1 and not some other 
parallel pathway governing mitotic entry.  To address this possibility we, treated 
synchronized control transfected or stathmin-depleted cells with a double thymidine 
block, released them into media containing DMSO or a combination of 300nM S1451 
and BI2536 and then determined mitotic index at timepoints for the next 14 hours.  We 
found that control transfected cells released into S1451 and BI2536, stathmin-depleted 
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cells released into DMSO and stathmin-depleted cells released into S1451 and BI2536 all 
had a peak of mitotic entry at 12 hours post release versus control transfected cells 
released into DMSO at 8 hours post release (Figure 2.6, C).  Combined depletion of 
stathmin and chemical inhibition of AURKA and PLK1 does not augment the duration of 
the delay caused by either treatment alone.  These data demonstrate the combined partial 
inhibition of AURKA and Plk1 is sufficient to delay mitotic entry, indicating that 
stathmin depletion slows cell cycle progression by the combined inhibition of two 
enzymes. 
 
MTs are required for AURKA centrosomal localization and activation 
 Previously we demonstrated that the interphase delay caused by stathmin 
depletion required MTs since nocodazole-induced MT depolymerization alleviated the 
delay during G2 (Carney et al., 2012). The results described above indicate that stathmin 
depletion reduced the amount of active AURKA and Plk1 enzymes, and that partial 
inhibition of the two enzymes was sufficient to delay mitotic entry. To probe whether 
MTs serve as a signal relay between stathmin and these enzymes, we first examined 
whether MTs were required for activation of AURKA in cells expressing stathmin at 
endogenous levels. Hela cells were incubated in 33 µM nocodazole for 3 h prior to 
fixation, sufficient to depolymerize all MTs (data not shown).  Surprisingly, AURKA 
centrosomal localization and activation were blocked significantly by MT 
depolymerization. AURKA was clearly visible in the cytoplasm but did not accumulate 
on centrosomes in Hela cells treated with nocodazole (Figure 2.5, A, upper). We also did 
not detect active AURKA, as marked by T288P (Figure 2. 5, A, lower) in nocodazole-
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treated cells. Since we found that AURKA required MTs to localize at the centrosome 
and become active, it was not surprising that AURKA activity was not restored by 
nocodazole treatment of stathmin-depleted cells (data not shown). These data indicate 
that AURKA requires an intact MT cytoskeleton for centrosome localization and 
activation, independent of stathmin level.  
 Stathmin depletion increases MT polymer level in a number of cell types (Howell 
et al., 1999; Holmfeldt et al., 2007; Sellin et al., 2008, see below), and this increased 
polymer could interfere with AURKA activation at centrosomes by slowing its 
translocation to the centrosome in G2 or by interfering with its proper localization to 
centrosomes. To test the first possibility, we measured the percentage of centrosomes 
staining positive for AURKA in cells fixed at various times after release from a double 
thymidine block. The timing of AURKA localization to centrosomes was unaffected by 
stathmin depletion indicating that trafficking of AURKA to the centrosome is not altered 
by stathmin depletion (Figure 2.5 B). In measuring AURKA levels at centrosomes, we 
consistently observed a wider distribution of AURKA in the centrosome region of 
stathmin-depleted cells. Quantitative measurements of the width of AURKA or active 
AURKA (T288P) localization confirmed this impression (Figure 2.5, C and D). While γ-
tubulin distribution was identical in control-transfected and stathmin-depleted cells 
(Figure 5 E and F), AURKA, or the active enzyme, was spread over a significantly wider 
area in stathmin-depleted cells. This localization included puncta that likely represent 
MT-bound enzyme. In C. elegans, AIR-1 (AURKA homolog) is also localized to both 
MTs and centrosomes (Toya et al., 2011). Assuming that AURKA is distributed in a 
 33 
spherical shape near the centrosome, our data indicate that the widening of AURKA 
localization is equivalent to an ~ 2 fold dilution in local concentration.  
 
Microtubule depolymerization restores Plk1 activation in stathmin-depleted cells 
 We next asked whether Plk1 activation is regulated by MTs, beginning with cells 
expressing stathmin at endogenous levels. Cells were incubated in 33 µM nocodazole for 
3 h to depolymerize MTs and levels of active Plk1 measured with an antibody specific 
for Plk1 phosphorylated at T210. Active Plk1 levels were unchanged by MT 
depolymerization compared to DMSO treated cells, indicating that MT depolymerization 
did not contribute significantly to Plk1 activation (Figure 2.8 A).  
 We previously showed that MT depolymerization abrogates the G2 cell cycle 
delay caused by stathmin depletion (Carney et al., 2012). Therefore, we next asked 
whether MT depolymerization abrogates the delay by restoring active Plk1. We depleted 
stathmin in Hela cells and approximately 45 hours after transfection treated cells with 33 
µM nocodazole for 3 hours, a concentration and time period previously determined 
sufficient to depolymerize all MTs and restore the population of cells in G2 to the level 
measured in siGLO treated control cells (with or without an intact MT cytoskeleton; 
Carney et al., 2012).  Nocodazole treatment partially rescued activation of Plk1 in 
stathmin-depleted cells. We found that Plk1 T210P was reduced to 35% of control level 
after stathmin depletion, and that incubation with nocodazole restored activity to 82% of 
the control value (Figure 2.8, B). It is likely that the restored Plk1 activity was sufficient 
to abrogate the G2 cell cycle delay since it is only when both enzymes were inhibited that 
a delay was observed. 
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Plk1 recruitment to centrosomes was delayed in stathmin-depleted cells 
 The data presented above indicate that stathmin depletion reduced active Plk1, at 
least partially via the MT cytoskeleton. Reduced activation of Plk1, measured within the 
nucleus, could result from either loss of centrosome localization where it is activated 
(Lens et al., 2010), or reduced nuclear import and/or nuclear retention of the active 
kinase.  Nuclear import and/or nuclear retention of active Plk1 do not appear dependent 
on stathmin levels since the ratio of active Plk1 in the nucleus vs. the cytoplasm was the 
same in control-transfected and stathmin-depleted cells (Figure 2.8, C).  In contrast, Plk1 
localization to the centrosome was delayed by about 3 h, measured by fixing cells at 
various times after release from a double thymidine block and staining with an antibodies 
to Plk1 and g-tubulin (Figure 2.8, D).  Delayed translocation of Plk1 from the cytoplasm 
to centrosomes could result from MT-based tethering to retain the enzyme in the 
cytoplasm. We tested this possibility by MT depolymerization, shown above to restore 
active Plk1 to near control levels. Surprisingly, MT depolymerization (3 h incubation in 
33 µM nocodazole) had no effect on the delayed localization of Plk1 to centrosomes, 
measured by the percent of centrosomes staining positive for Plk1 at 9 or 12 h post-
release from a double thymidine block (Figure 2.8, E).  Taken together with our data 
showing near complete restoration of active Plk1 in stathmin-depleted cells treated with 
nocodazole, these data indicate that Plk1 activation can occur in the absence of MTs and 
without centrosome localization. To date, the mechanism of Plk1 activation at the 
centrosome is poorly understood (Soung et al., 2009), and alternative activation pathways 
are not yet known. 
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Stathmin overexpression decreased Plk1 activation  
 Activation of AURKA and Plk1 in G2 are partially inhibited by stathmin 
depletion and/or the resulting increase in MTs.  To probe whether either enzyme's 
activation is dependent on stathmin level over a broad range of concentrations, we next 
asked whether stathmin over-expression leads to greater or lesser activation of AURKA 
and Plk1 compared to cells expressing stathmin at endogenous levels.  We depleted 
stathmin in Hela cells using siRNA targeting its 5’ untranslated region and exogenously 
expressed stathmin from a plasmid encoding stathmin-GFP or CFP (Ringhoff and 
Cassimeris, 2009). Western blots of Hela cells transfected with stathmin siRNA and/or 
STMN-GFP (or CFP) plasmid showed that stathmin level is reduced significantly after 
transfection with the 5' UTR-targeted siRNA and that stathmin-CFP is expressed at a 
greater level than endogenous stathmin with or without concomitant knockdown of the 
endogenous protein (Figure 2.9, A and B). MT density was proportional to stathmin 
level, yet modest since MTs retained their typical interphase organization (Figure 2.10, A 
and B). 
 Stathmin overexpression did not effect AURKA activation, and expression of 
stathmin-CFP was sufficient to restore active AURKA to control levels in cells depleted 
of endogenous stathmin (Figure 2.9, C).  Interestingly, Plk1 activation was significantly 
decreased by stathmin overexpression, as well as by stathmin depletion, indicating that 
full Plk1 activation requires stathmin expression within certain limits. Stathmin-CFP 
expression in cells depleted of endogenous stathmin was sufficient to restore Plk1 
activation and to restore normal timing for mitotic entry, as measured by the proportion 
of cells staining positive for several G2 markers (Figure 2.9 D).  
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Stathmin interacts with AURKA and Plk1 in vitro 
 Our data indicate that stathmin expression level acts upstream to regulate 
AURKA and Plk1 activation at mitotic entry, and that this upstream signal pathway is at 
least partially relayed via MTs.  To probe whether stathmin is also a downstream target of 
these enzymes, as expected if these proteins function in a negative feedback loop, we 
examined whether purified, active kinases can phosphorylate stathmin in vitro.  Stathmin 
contains 4 serine phosphorylation sites and two of these, S16 and S63, contain a 
consensus sequence for AURKA phosphorylation (Sardon et al., 2010 and Gadea and 
Ruderman, 2006). In vitro, purified stathmin was phosphorylated by AURKA and this 
phosphorylation was lost when Serine 16 and Serine 63 were mutated to alanine, 
indicating that one or both of these sites were phosphorylated by AURKA (Figure 2.11, 
A and B).  
 While stathmin is readily phosphorylated by AURKA, it is not a substrate for 
Plk1 (Figure 2.11, C) consistent with negative results from phospho-proteomic screens to 
identify all Plk1 targets (Santamaria et al., 2011 and Grosstessner-Hain et al., 2011). In 
the course of our in vitro experiments, we routinely saw that active Plk1 underwent 
autophosphorylation and incorporated radioactive phosphate, but that samples containing 
stathmin inhibited this autophosphorylation reaction.  Inhibition of Plk1 
autophosphorylation was dependent on stathmin concentration and was most easily 
detected at high molar ratios of stathmin/Plk1 (Figure 2.11, D).  The concentration of 
Plk1 in Hela cells is not known, but is likely considerably lower than that of stathmin 
(500 - 1000 ng/mg total protein has been measured in transformed cells (Brattsand et al., 
1993) and the molar ratios tested here are feasible ratios within cells. 
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Discussion:  
Stathmin depletion reduces AURKA and Plk1 activation  
Cells depleted of stathmin are slower to proliferate (Zhang et al., 2006; Chen et al., 2007; 
Wang et al., 2007; Carney and Cassimeris, 2010) and are delayed during G2 (Carney and 
Cassimeris, 2010; Carney et al., 2012). Here we explored the mechanism responsible for 
this delay and found that stathmin depletion leads to less active CDC25 by reducing the 
activation of both AURKA and Plk1. Chemical inhibition of AURKA and Plk1 
separately or in combination demonstrated that both enzymes must be partially inhibited 
to significantly delay cells during G2.  
 Previous studies suggested that reduced levels of both stathmin and p53 were 
required for delayed cell proliferation, which represents a combination of slower cell 
cycle progression and cell death (Alli et al., 2007, Carney and Cassimeris, 2010). Our 
current study indicates that increased p53 expression (by restoring p53 in Hela cells) 
reduced Plk1 expression (see also, McKenzie et al., 2010) but did not reduce AURKA 
expression or activation. Therefore, we conclude that stathmin depletion, and not loss of 
p53, is responsible for delayed mitotic entry. In contrast, cell death likely requires loss of 
both stathmin and p53 (Alli et al., 2007, Carney and Cassimeris, 2010). 
 Chemical inhibitor studies support the idea that simultaneous inhibition of both 
AURKA and Plk1 delays mitotic entry (Van Horn et al., 2010), while inhibition of a 
single enzyme does not (Lenart 2007; Van Horn et al., 2010).  Either inhibitor is 
sufficient to block cells in mitosis (Steegmaier et al., 2007; Gleixner et al., 2010; 
Grinshtein et al., 2011; Hoar et al., 2007; Fu et al., 2012; Yuan et al.,  2012). Computer 
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simulations support the idea that partial inhibition of both AURKA and Plk1 
synergistically inhibit CDK1 activation (Zou et al., 2011). Given the feedback loops 
among enzymes driving mitotic entry, combinations of other enzymes regulating cell 
cycle progression should slow mitotic entry, as predicted in simulations combining Plk1 
inhibition and a DNA damage response (Kesseler et al., 2013).  
 Several other factors also slow entry into mitosis by inhibiting activation of 
AURKA, Plk1 or both enzymes. Clostridium difficile Toxin B inhibits Rho GTPase 
activity, delays AURKA activation and prolongs G2, but Plk1 activation was not 
measured (Ando et al., 2007). Disruption of Golgi fragmentation also delayed cells in G2 
and reduced AURKA recruitment to centrosomes (Persico et al., 2010), but whether 
diminished recruitment causes the delay is unknown (Cervigni et al. 2011). Finally, 
knockdown of G Protein Coupled Receptor Kinase 5 reduced MT nucleation from the 
centrosome, delayed mitotic entry, and inhibited both AURKA and Plk1 (Michal et al., 
2012). 
  
Stathmin regulates AURKA and Plk1 partially via MTs 
 While stathmin depletion inhibits activation of AURKA and Plk1, it does not 
appear to activate known checkpoint pathways that can inhibit mitotic entry, making it 
unlikely that stathmin depletion acts upstream of these pathways. It is possible that 
stathmin functions as a downstream relay, communicating inhibitory signals from an 
activated checkpoint to reduce the activities of AURKA, Plk1 and CDC25. Stathmin 
depletion decreased AURKA and Plk1 activation via a process partially dependent on 
MTs (summarized in Figure 2.12 and discussed below) since we previously showed that 
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MT depolymerization, by a 3 h incubation in nocodazole, was sufficient to remove the 
G2 cell cycle delay induced by stathmin depletion (Carney et al., 2012). 
 Diagrams in Figure 2.12 summarize the MT and stathmin dependent regulation of 
AURKA and Plk1. MT depolymerization (at endogenous stathmin levels) inhibited 
AURKA localization to the centrosome and subsequent activation. Plk1 was activated 
normally under these conditions.  Both AURKA and Plk1 were also activated normally in 
cells treated with 10 nM paclitaxel (our unpublished observations). This low 
concentration of paclitaxel is sufficient to block cells at metaphase (Jordan et al. 1993) 
but allows MTs to remain dynamic (our unpublished observations) and does not slow 
mitotic entry (Carney et al., 2012). Stathmin depletion inhibited both AURKA and Plk1 
activation, while stathmin overexpression inhibited Plk1 activation, likely through a 
direct interaction. Thus, stathmin depletion is unique in inhibiting both AURKA and 
Plk1, and it is only under these conditions that we measure a delayed entry into mitosis.  
 The MT-based regulation of AURKA is demonstrated by the MT-dependent 
localization and subsequent activation of AURKA at the centrosome. Stathmin depletion 
also inhibits AURKA activation, but not recruitment to the centrosome. Stathmin 
depletion increases centrosomal MT nucleation rate, increases MT polymer (Larsson et 
al., 1997; Ringhoff and Cassimeris 2009; Carney and Cassimeris, 2010), and increases 
the density of MTs near the centrosome (Cassimeris, unpublished observations). The 
distribution of AURKA across a wider area near the centrosome in stathmin-depleted 
cells is likely a consequence of excess MTs, given the MT requirement for AURKA 
localization. This broadening of AURKA distribution is equivalent to protein dilution; 
reducing local AURKA concentration should reduce dimer formation and limit 
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autophosphorylation reactions, as shown experimentally in vitro (Joukov et al. 2010) and 
by computational modeling (Zou et al., 2011).  
 Plk1 activation also depends on both stathmin and MTs. Stathmin depletion 
inhibited Plk1 activation and delayed Plk1 recruitment to centrosomes. Curiously MT 
depolymerization did not prevent Plk1 binding to centrosomes, and did not rescue the 
time delay in Plk1 arrival at the centrosomes of stathmin-depleted cells, yet restored 
active Plk1 in cells depleted of stathmin. These data indicate that Plk1 recruitment and 
retention at centrosomes is not solely dependent on MTs. Purified stathmin inhibited Plk1 
autophosphorylation in vitro, as did stathmn-CFP overexpression, demonstrating that 
stathmin can directly regulate Plk1. 
 The mechanisms underlying Plk1 localization to the centrosome and activation at 
this site are still poorly understood. In Drosophila, Plk1 is tethered to interphase MTs 
through its binding to MAP205, a MAP4 homolog (Archambault et al., 2008). Release 
from MTs/MAP205 then allows Plk1 activation. Stathmin depletion could decrease Plk1 
activation via increased tethering to MTs. While this mechanism would explain the 
ability of MT depolymerization to restore Plk1 activity to near control levels in stathmin-
depleted cells, it does not explain the MT-independent delay in Plk1 localization to 
centrosomes. How Plk1 is recruited or targeted to centrosomes has not been studied 
thoroughly, but involves anchoring proteins, which are themselves regulated by CDK1 
(Soung et al., 2009). MT depolymerization restores Plk1 activity sufficiently to relieve 
the delay in G2, but does not also restore timely centrosome recruitment, implying that 
the activation step is more complex than currently thought. 
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Conclusions 
 In summary, our results demonstrate a previously unrecognized communication 
between stathmin and the MT cytoskeleton with the enzymes AURKA, Plk1 and CDC25 
that drive CDK1/cyclin B activation for timely entry into mitosis. While stathmin 
depletion likely regulates AURKA and Plk1 in part via MT polymers, the precise 
mechanism regulating each enzyme is not yet clear. The MT-dependent signal relay 
cannot simply reflect a general MT stability since paclitaxel at nanomolar concentrations 
stabilizes MTs to some extent (Jordan et al., 1993; our unpublished observations) but 
does not slow interphase progression (Carney et al., 2012). Therefore, small molecule 
inhibitors (Liang et al., 2008) or ribozymes to decrease stathmin expression (Mistry et 
al., 2005) should target cell processes distinct from those targeted by paclitaxel.  
 
Materials and Methods: 
Cell Culture and Plasmid Transfections:  Hela cells were grown in DMEM (Sigma) 
supplemented with 10% fetal bovine serum (FBS; Invitogen) and 1X 
antibiotic/antimycotic (Sigma). In some experiments, Hela cells were synchronized 
through a double thymidine block by overnight incubation in 5mM thymidine (in 
DMEM), 8 h release in DMEM after 5 washes in warm PBS and then 16 h incubation in 
5mM thymidine (in DMEM). Cells were transferred to DMEM following 5 washes with 
warm PBS and fixed at time points.  For RNAi in synchronized cells, transfections were 
performed during the first 8 h release of the double thymidine block.  
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 In some experiments Hela cells were transfected with plasmids for expression of 
stathmin-GFP or stathmin-CFP (Ringhoff and Cassimeris, 2009) using X-tremeGENE 
HP DNA Transfection Reagent (version 1.0; Roche Diagnostics, Indianapolis, IN) 
according to the manufacturer's protocol.  When transfected with both siRNA and 
plasmids, plasmid transfection was performed 5 hours after siRNA and samples were 
fixed 43 hours after the second transfection.  
 
Drugs and Reagents:  Chemical inhibitors to Plk1 (BI 2536, Grinshtein et al., 2011), 
and AURKA (S 1451, Yuan et al., 2011) were purchased from Selleckchem. All other 
reagents were from Sigma unless noted otherwise. 
 
RNA Interference and Transient Transfection:  Cells were grown in 35mm dishes and 
transfected with siRNAs using GeneSilencer (Genlantis) 1-2 days after plating according 
to the manufacturer’s protocol. Cells were serum starved from the time of transfection to 
four hours post-transfection to improve efficiency. siRNA oligonucleotides 
(Thermoscientific/Dharmacon) used were SMTN1 (Op18-443), 5’- 
CGUUUGCGAGAGAAGGAUAdtdt-3’, STMN1 5’UTR 
CCCAGUUGAUUGUGCAGAAUU  and HPV E6 (18E6-385), 5’-
CUAACACUGGGUUAUACAAdtdt-3’ (restores p53 by depleting the HPV E6 protein) 
(Koivusalo et al., 2005). SiGlo Risc-Free siRNA (Dharmacon) or siGenome non-
targeting siRNA (Thermoscientific/Dharmacon) were used as control siRNA sequences 
for these experiments.  
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Indirect Immunofluorescence and confocal microscopy: Hela cells were grown on 
glass coverslips and treated as described above. They were either fixed with 4% 
Paraformaldehyde (Electron Microscopy Services)/20% glycerol in PEM (100 mM Pipes, 
1 mM MgSO4, 2 mM EGTA, pH 6.9) for 10 minutes at room temperature or with 
methanol supplemented with 1mM EDTA at -20oC for 10 minutes. Cells fixed with 
paraformaldehyde/glycerol were permeabilized with methanol at -20oC for 10 minutes. 
Fixed cells were incubated with blocking reagent (10% FBS in phosphate buffered saline, 
PBS) for 30 minutes at 37oC followed by a 45-minute incubation with primary antibody 
at 37oC. Cells were then washed with PBS and incubated with secondary antibody and 
1.5 µM propidium iodide for an additional 45 minutes at 37oC. Antibodies used included: 
anti-phospho-Aurora A (T288) (1:1000, Cell Signaling), anti-phospho-Plk1 (T210) 
(1:1000, BD Pharmingen), anti-Aurora A (1:100, Cell Signaling), anti-Plk1 (Millipore) 
and Goat anti-mouse or anti-rabbit Alexa Fluor 488 or 568 (1:50, Invitrogen). Coverslips 
were then washed with PBS and mounted on slides with Vectashield (Vector Labs). Cells 
were imaged as described previously (Piehl and Cassimeris, 2003) using 63X/1.4 
numerical aperture plan apo objective on an inverted microscope (Zeiss Axiovert 200M). 
 For synchronized cells mitotic index was determined by staining with propidium 
iodide and counting cells with condensed chromatin as a percent of total cells. At least 
ten fields (coverslip positions, > 100 cells per time point) were counted for each 
treatment group. For time course studies, cells were stained for either AURKA or Plk1 
along with γ-tubulin (to label centrosomes) and TO-PRO 3 (to label DNA, Invitrogen).  
The percent of cells with visible centrosomes positive for AURKA or Plk1 were counted 
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for at least 5 fields (coverslip positions, >100 cells per time point) for each treatment 
group.  
 For quantitative measurement of fluorescence, maximum intensity projections 
were made from Z-stacks in Zeiss LSM viewer and exported as tiff files to MetaMorph. 
Fluorescence intensity from standard regions of interest (ROIs) was integrated and 
background intensity (average of 2 standard areas outside of ROI) subtracted. Values 
were normalized by setting the average control value to 100 for each individual 
experiment. Normalized data were then pooled for all experiments. For distribution 
measurements of AURKA and γ-tubulin, intensities along a line scan of the centrosome 
region of the cell were recorded.  Values along the line that were continuously two-fold 
over background were used to determine width of AURKA and γ-tubulin distribution.   
 
Western Blotting: Soluble cell extracts were prepared as described previously (Carney 
and Cassimeris, 2010) and protein concentrations were measured by Bradford assay. 
Lysates were diluted in PAGE sample buffer, 10 µg total protein per lane was typically 
loaded and resolved in 10% polyacrylamide gels and transferred to Immobilon 
Membranes (Millpore, Billerica, MA). Membranes were blocked with 5% non-fat milk or 
5% BSA (for phospho-antibodies) in Tris-buffered saline with 0.1% Tween and then 
probed with primary antibodies: anti-Aurora A (1:1000 Cell Signaling), anti-Plk1 
(1:1000, Millipore), anti-Plk1 T210P (1:1000, BD Pharmingen) or anti-stathmin (1:2000, 
Sigma) followed by secondary antibodies, anti-mouse (1:2000; Abcam) or anti-rabbit 
(1:10,000, BD Biosciences) horseradish peroxidase-linked IgG. Immunoreactive bands 
were developed using enhanced chemiluminscence (GE Amersham). Membranes were 
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reprobed with anti-α-tubulin (1:1000, Sigma) or GAPDH (1:1000, Abcam) as a loading 
control.  
 
Live Cell Imaging:  To follow cell fates over several days, Hela cells were plated on 
Mattek dishes and imaged using a Nikon Biostation IM as described previously (Carney 
et al., 2012). Cells were imaged with phase contrast optics using a 20X objective and 
images were collected at 5-minute intervals for 24-72 hours. Cell fates were tracked from 
image series. Mitotic entry was marked either by the first image showing loss of the 
nuclear envelope or by significant cell rounding. Mitotic exit was marked as the first 
image showing formation of cleavage furrow, indicating the start of cytokinesis.  
 
In vitro protein expression and kinase assays: Sequences encoding stathmin-FLAG, 
stathmin-S16,63A-FLAG, stathmin-S25,38A-FLAG, stathmin- ∆5-25-FLAG, and 
stathmin-∆100-147-FLAG (each including Nco1 and BamH1 restriction sites) were 
generated by total gene synthesis and inserted into the Nco1 and BamH1 sites of the pET-
28a plasmid (gene synthesis, cloning and sequence verifications performed by Genewiz, 
South Plainfield, NJ). Plasmids were transfected into E. coli and protein expression 
induced with 1 mM IPTG for 1-3 hours. Cells were pelleted and resuspended in TBS, 
0.1% NP-40, protease inhibitor cocktail (ThermoScientific) and PMSF. E. coli were lysed 
by sonication, clarified, boiled for 10 minutes, and the final clarified supernatants frozen 
at -20°C. Stathmin is heat stable and the final supernatant fraction was > 90% stathmin 
based on Coomassie Blue stained SDS gels and confirmed by immunoblots probed with 
anti-stathmin (a combination of rabbit antibodies recognizing the C terminus (Sigma) and 
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a region around amino acid 38 (Cell Signaling) to detect all mutants) and anti-FLAG 
(M2, Sigma). 
 For in vitro kinase assays, purified stathmin-FLAG or mutants (7.6 µM when 
used as an enzyme substrate or 0.1 - 3 µM for Plk1 inhibition experiments) in kinase 
buffer (20 mM HEPES, 10 mM MgCl2, 10 mM KCl, 1 µM DTT, 100 µg/mL BSA, 
0.01% NP-40) were incubated with 5 µM ATP, 5 µCi [32P]-ATP (Perkin Elmer, 6000 
Ci/mmol), and either active AURKA (0.6 nM; from Millipore (Dundee, UK) or Prospec-
Tany TechnoGene Ltd. (Ness Ziona, Israel)) or active Plk1 (70-140 nM; Signal Chem, 
British Columbia, Canada) for 30 m at 30°C. In additional experiments, 
dephosphorylated casein (Sigma) was used as a Plk1 substrate (Steegmaier et al., 2007). 
The final concentration of casein in these reactions was 3 µM. The BSA concentration in 
the standard reaction mixture was 1.5 µM; where noted the BSA concentration was raised 
to 7.5 µM to test whether excess protein inhibits Plk1 activity. Reactions were stopped by 
adding 5X SDS sample buffer and heating to 70°C for 10 m. Proteins were separated on 
10% PAGE-gels, stained with Coomassie Blue, wet gels were exposed to 
phosphorImager screens for 1 - 5 hours and imaged with a Storm 840 PhosphorImager 
(Amersham Biosciences). 
 
Data Analysis: Statistical analysis of fluorescence intensity and cell cycle durations were 
performed using unpaired t-tests with GraphPad Software 
(www.graphpad.com/quickcalcs/ttest1.cfm).  
  
 47 
References: 
1. Aliagas-Martin et al. (2009). A class of 2,4-bisanilinopyrimidine Aurora A inhibitors 
with unusually high selectivity against Aurora B. Journal of medicinal chemistry 52, 
3300-3307. 
2. Alli, E., Bash-Babula, J., Yang, J.M., and Hait, W.N. (2002). Effect of stathmin on 
the sensitivity to antimicrotubule drugs in human breast cancer. Cancer research 62, 
6864-6869. 
3. Alli, E., Yang, J.M., Ford, J.M., and Hait, W.N. (2007). Reversal of stathmin-
mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells. 
Molecular pharmacology 71, 1233-1240. 
4. Ando, Y., Yasuda, S., Oceguera-Yanez, F., and Narumiya, S. (2007). Inactivation of 
Rho GTPases with Clostridium difficile toxin B impairs centrosomal activation of 
Aurora-A in G2/M transition of HeLa cells. Molecular biology of the cell 18, 3752-
3763. 
5. Archambault, V., D'Avino, P.P., Deery, M.J., Lilley, K.S., and Glover, D.M. (2008). 
Sequestration of Polo kinase to microtubules by phosphopriming-independent binding 
to Map205 is relieved by phosphorylation at a CDK site in mitosis. Genes & 
development 22, 2707-2720. 
6. Belletti, B., and Baldassarre, G. (2011). Stathmin: a protein with many tasks. New 
biomarker and potential target in cancer. Expert opinion on therapeutic targets 15, 
1249-1266. 
7. Brattsand, G., Roos, G., Marklund, U., Ueda, H., Landberg, G., Nanberg, E., Sideras, 
P., and Gullberg, M. (1993). Quantitative-analysis of the expression and regulation of 
an activation-regulated phosphoprotein (oncoprotein 18) in normal and neoplastic-
cells. Leukemia 7, 569-579. 
8. Carney, B.K., Caruso Silva, V., and Cassimeris, L. (2012). The microtubule 
cytoskeleton is required for a G2 cell cycle delay in cancer cells lacking stathmin and 
p53. Cytoskeleton (Hoboken) 69, 278-289. 
 48 
9. Carney, B.K., and Cassimeris, L. (2010). Stathmin/oncoprotein 18, a microtubule 
regulatory protein, is required for survival of both normal and cancer cell lines 
lacking the tumor suppressor, p53. Cancer biology & therapy 9, 699-709. 
10. Cervigni, R.I., Barretta, M.L., Persico, A., Corda, D., and Colanzi, A. (2011). The 
role of Aurora-A kinase in the Golgi-dependent control of mitotic entry. 
Bioarchitecture 1, 61-65. 
11.  Chen, Y., Lin, M.C., Yao, H., Wang, H., Zhang, A.Q., Yu, J., Hui, C.K., Lau, G.K., 
He, M.L., Sung, J., and Kung, H.F. (2007). Lentivirus-mediated RNA interference 
targeting enhancer of zeste homolog 2 inhibits hepatocellular carcinoma growth 
through down-regulation of stathmin. Hepatology 46, 200-208. 
12. Dutertre et al., (2004). Phosphorylation of CDC25B by Aurora-A at the centrosome 
contributes to the G2-M transition. Journal of cell science 117, 2523-2531. 
13.  Efimov, A., and Kaverina, I. (2009). Significance of microtubule catastrophes at 
focal adhesion sites. Cell adhesion & migration 3, 285-287.  
14.  Eyers, P.A., Erikson, E., Chen, L.G., and Maller, J.L. (2003). A novel mechanism for 
activation of the protein kinase Aurora A. Current biology : CB 13, 691-697. 
15.  Ezratty, E.J., Partridge, M.A., and Gundersen, G.G. (2005). Microtubule-induced 
focal adhesion disassembly is mediated by dynamin and focal adhesion kinase. 
Nature cell biology 7, 581-590. 
16. Fu, S., Li, Y., Huang, J., Liu, T., Hong, Z., Chen, A., Bast, R.C., Kavanagh, J.J., 
Gershenson, D.M., Sood, A.K., and Hu, W. (2012). Aurora kinase inhibitor VE 465 
synergistically enhances cytotoxicity of carboplatin in ovarian cancer cells through 
induction of apoptosis and downregulation of histone 3. Cancer biology & therapy 13, 
1034-1041. 
17. Gadea, B.B., and Ruderman, J.V. (2006). Aurora B is required for mitotic chromatin-
induced phosphorylation of Op18/Stathmin. Proceedings of the National Academy of 
Sciences of the United States of America 103, 4493-4498. 
18.  Gleixner, K.V. et al. (2010). Polo-like kinase 1 (Plk1) as a novel drug target in 
chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 
2536. Cancer research 70, 1513-1523. 
 49 
19.  Grinshtein, N., Datti, A., Fujitani, M., Uehling, D., Prakesch, M., Isaac, M., Irwin, 
M.S., Wrana, J.L., Al-Awar, R., and Kaplan, D.R. (2011). Small molecule kinase 
inhibitor screen identifies polo-like kinase 1 as a target for neuroblastoma tumor-
initiating cells. Cancer research 71, 1385-1395. 
20. Grosstessner-Hain et al. (2011). Quantitative phospho-proteomics to investigate the 
polo-like kinase 1-dependent phospho-proteome. Molecular & cellular proteomics : 
MCP 10, M111 008540. 
21.  Gundersen, G.G., and Cook, T.A. (1999). Microtubules and signal transduction. 
Current opinion in cell biology 11, 81-94. 
22. Hoar, K., Chakravarty, A., Rabino, C., Wysong, D., Bowman, D., Roy, N., and 
Ecsedy, J.A. (2007). MLN8054, a small-molecule inhibitor of Aurora A, causes 
spindle pole and chromosome congression defects leading to aneuploidy. Molecular 
and cellular biology 27, 4513-4525. 
23. Holmfeldt, P., Stenmark, S., and Gullberg, M. (2007). Interphase-specific 
phosphorylation-mediated regulation of tubulin dimer partitioning in human cells. 
Molecular biology of the cell 18, 1909-1917. 
24. Holmfeldt, P., Sellin, M.E., and Gullberg, M. (2009). Predominant regulators of 
tubulin monomer-polymer partitioning and their implication for cell polarization. 
Cellular and molecular life sciences : CMLS 66, 3263-3276. 
25.  Howell, B., Larsson, N., Gullberg, M., and Cassimeris, L. (1999). Dissociation of the 
tubulin-sequestering and microtubule catastrophe-promoting activities of oncoprotein 
18/stathmin. Molecular biology of the cell 10, 105-118. 
26. Izumi, T., and Maller, J.L. (1993). Elimination of cdc2 phosphorylation sites in the 
cdc25 phosphatase blocks initiation of M-phase. Molecular biology of the cell 4, 
1337-1350. 
27. Johnsen, J.I., Aurelio, O.N., Kwaja, Z., Jorgensen, G.E., Pellegata, N.S., Plattner, R., 
Stanbridge, E.J., and Cajot, J.F. (2000). p53-mediated negative regulation of 
stathmin/Op18 expression is associated with G(2)/M cell-cycle arrest. International 
journal of cancer. Journal international du cancer 88, 685-691. 
 50 
28. Jordan, M.A., Toso, R.J., Thrower, D., and Wilson, L. (1993). Mechanism of mitotic 
block and inhibition of cell proliferation by taxol at low concentrations. Proceedings 
of the National Academy of Sciences of the United States of America 90, 9552-9556. 
29. Jordan, M.A., and Wilson, L. (2004). Microtubules as a target for anticancer drugs. 
Nature reviews. Cancer 4, 253-265. 
30. Jordan, M.A., and Kamath, K. (2007). How do microtubule-targeted drugs work? An 
overview. Current cancer drug targets 7, 730-742. 
31.  Joukov, V., De Nicolo, A., Rodriguez, A., Walter, J.C., and Livingston, D.M. (2010). 
Centrosomal protein of 192 kDa (Cep192) promotes centrosome-driven spindle 
assembly by engaging in organelle-specific Aurora A activation. Proceedings of the 
National Academy of Sciences of the United States of America 107, 21022-21027. 
32.  Kang, Y.H., Park, J.E., Yu, L.R., Soung, N.K., Yun, S.M., Bang, J.K., Seong, Y.S., 
Yu, H., Garfield, S., Veenstra, T.D., and Lee, K.S. (2006). Self-regulated Plk1 
recruitment to kinetochores by the Plk1-PBIP1 interaction is critical for proper 
chromosome segregation. Molecular cell 24, 409-422. 
33.  Katayama, H., Sasai, K., Kloc, M., Brinkley, B.R., and Sen, S. (2008). Aurora 
kinase-A regulates kinetochore/chromatin associated microtubule assembly in human 
cells. Cell Cycle 7, 2691-2704. 
34.  Kesseler, K.J., Blinov, M.L., Elston, T.C., Kaufmann, W.K., and Simpson, D.A. 
(2013). A predictive mathematical model of the DNA damage G2 checkpoint. Journal 
of theoretical biology 320, 159-169. 
35.  Kishi, K., van Vugt, M.A., Okamoto, K., Hayashi, Y., and Yaffe, M.B. (2009). 
Functional dynamics of Polo-like kinase 1 at the centrosome. Molecular and cellular 
biology 29, 3134-3150. 
36.  Koivusalo, R., Krausz, E., Helenius, H., and Hietanen, S. (2005). Chemotherapy 
compounds in cervical cancer cells primed by reconstitution of p53 function after 
short interfering RNA-mediated degradation of human papillomavirus 18 E6 mRNA: 
opposite effect of siRNA in combination with different drugs. Molecular 
pharmacology 68, 372-382. 
 51 
37. Kramer, A., Lukas, J., and Bartek, J. (2004). Checking out the centrosome. Cell Cycle 
3, 1390-1393. 
38. Larsson, N., Marklund, U., Gradin, H.M., Brattsand, G., and Gullberg, M. (1997). 
Control of microtubule dynamics by oncoprotein 18: dissection of the regulatory role 
of multisite phosphorylation during mitosis. Molecular and cellular biology 17, 5530-
5539. 
39.  Lee, K.S., Oh, D.Y., Kang, Y.H., and Park, J.E. (2008). Self-regulated mechanism of 
Plk1 localization to kinetochores: lessons from the Plk1-PBIP1 interaction. Cell 
division 3, 4. 
40. Leinung, M., Cuny, C., Diensthuber, M., Stover, T., and Wagenblast, J. (2012). Small 
molecules in combination with conventional chemotherapeutic drugs: Light at the end 
of the tunnel? Oncology letters 4, 1043-1046. 
41.  Lenart, P., Petronczki, M., Steegmaier, M., Di Fiore, B., Lipp, J.J., Hoffmann, M., 
Rettig, W.J., Kraut, N., and Peters, J.M. (2007). The small-molecule inhibitor BI 
2536 reveals novel insights into mitotic roles of polo-like kinase 1. Current biology : 
CB 17, 304-315. 
42. Lens, S.M., Voest, E.E., and Medema, R.H. (2010). Shared and separate functions of 
polo-like kinases and aurora kinases in cancer. Nature reviews. Cancer 10, 825-841. 
43. Liang, X.J., Choi, Y., Sackett, D.L., and Park, J.K. (2008). Nitrosoureas inhibit the 
stathmin-mediated migration and invasion of malignant glioma cells. Cancer research 
68, 5267-5272. 
44.  Lindqvist, A., Rodriguez-Bravo, V., and Medema, R.H. (2009). The decision to enter 
mitosis: feedback and redundancy in the mitotic entry network. The Journal of cell 
biology 185, 193-202. 
45.  Lowery, D.M., Lim, D., and Yaffe, M.B. (2005). Structure and function of Polo-like 
kinases. Oncogene 24, 248-259. 
46.  Macurek, L., Lindqvist, A., Lim, D., Lampson, M.A., Klompmaker, R., Freire, R., 
Clouin, C., Taylor, S.S., Yaffe, M.B., and Medema, R.H. (2008). Polo-like kinase-1 is 
activated by aurora A to promote checkpoint recovery. Nature 455, 119-123.  
 52 
47. McKenzie, L et al. (2010). p53-dependent repression of polo-like kinase-1 (PLK1). 
Cell Cycle 9, 4200-4212. 
48.  Michal, A.M., So, C.H., Beeharry, N., Shankar, H., Mashayekhi, R., Yen, T.J., and 
Benovic, J.L. (2012). G Protein-coupled receptor kinase 5 is localized to centrosomes 
and regulates cell cycle progression. The Journal of biological chemistry 287, 6928-
6940. 
49.  Mistry, S.J., Bank, A., and Atweh, G.F. (2005). Targeting stathmin in prostate 
cancer. Molecular cancer therapeutics 4, 1821-1829. 
50.  Mitra, M., Kandalam, M., Sundaram, C.S., Verma, R.S., Maheswari, U.K., 
Swaminathan, S., and Krishnakumar, S. (2011). Reversal of stathmin-mediated 
microtubule destabilization sensitizes retinoblastoma cells to a low dose of 
antimicrotubule agents: a novel synergistic therapeutic intervention. Investigative 
ophthalmology & visual science 52, 5441-5448. 
51.  Molli, P.R., Li, D.Q., Bagheri-Yarmand, R., Pakala, S.B., Katayama, H., Sen, S., 
Iyer, J., Chernoff, J., Tsai, M.Y., Nair, S.S., and Kumar, R. (2010). Arpc1b, a 
centrosomal protein, is both an activator and substrate of Aurora A. The Journal of 
cell biology 190, 101-114. 
52.  Ohashi, S., Sakashita, G., Ban, R., Nagasawa, M., Matsuzaki, H., Murata, Y., 
Taniguchi, H., Shima, H., Furukawa, K., and Urano, T. (2006). Phospho-regulation of 
human protein kinase Aurora-A: analysis using anti-phospho-Thr288 monoclonal 
antibodies. Oncogene 25, 7691-7702. 
53. Perry, J.A., and Kornbluth, S. (2007). Cdc25 and Wee1: analogous opposites? Cell 
division 2, 12. 
54.  Persico, A., Cervigni, R.I., Barretta, M.L., Corda, D., and Colanzi, A. (2010). Golgi 
partitioning controls mitotic entry through Aurora-A kinase. Molecular biology of the 
cell 21, 3708-3721. 
55.  Piehl, M., and Cassimeris, L. (2003). Organization and dynamics of growing 
microtubule plus ends during early mitosis. Molecular biology of the cell 14, 916-
925. 
 53 
56.  Polager, S., and Ginsberg, D. (2003). E2F mediates sustained G2 arrest and down-
regulation of Stathmin and AIM-1 expression in response to genotoxic stress. The 
Journal of biological chemistry 278, 1443-1449. 
57.  Reinhardt, H.C et al. (2010). DNA damage activates a spatially distinct late 
cytoplasmic cell-cycle checkpoint network controlled by MK2-mediated RNA 
stabilization. Molecular cell 40, 34-49. 
58.  Rieder, C.L. (2011). Mitosis in vertebrates: the G2/M and M/A transitions and their 
associated checkpoints. Chromosome research : an international journal on the 
molecular, supramolecular and evolutionary aspects of chromosome biology 19, 291-
306. 
59.  Rieder, C.L., and Cole, R. (2000). Microtubule disassembly delays the G2-M 
transition in vertebrates. Current biology : CB 10, 1067-1070. 
60.  Ringhoff, D.N., and Cassimeris, L. (2009). Stathmin regulates centrosomal 
nucleation of microtubules and tubulin dimer/polymer partitioning. Molecular 
biology of the cell 20, 3451-3458. 
61.  Santamaria, A., Wang, B., Elowe, S., Malik, R., Zhang, F., Bauer, M., Schmidt, A., 
Sillje, H.H.W., Korner, R., and Nigg, E.A.  2011. The Plk1-dependent 
phosphoproteome of the early mitotic spindle.  Molecular and Cellular Proteomics. 
10, M110.004457. 
62. Sardon, T., Pache, R.A., Stein, A., Molina, H., Vernos, I., and Aloy, P. (2010). 
Uncovering new substrates for Aurora A kinase. EMBO reports 11, 977-984. 
63. Scheffner, M., Werness, B.A., Huibregtse, J.M., Levine, A.J., and Howley, P.M. 
(1990). The E6 oncoprotein encoded by human papillomavirus types 16 and 18 
promotes the degradation of p53. Cell 63, 1129-1136. 
64.  Scutt, P.J., Chu, M.L., Sloane, D.A., Cherry, M., Bignell, C.R., Williams, D.H., and 
Eyers, P.A. (2009). Discovery and exploitation of inhibitor-resistant aurora and polo 
kinase mutants for the analysis of mitotic networks. The Journal of biological 
chemistry 284, 15880-15893. 
 54 
65.  Seki, A., Coppinger, J.A., Jang, C.Y., Yates, J.R., and Fang, G. (2008). Bora and the 
kinase Aurora a cooperatively activate the kinase Plk1 and control mitotic entry. 
Science 320, 1655-1658. 
66.  Sellin, M.E., Holmfeldt, P., Stenmark, S., and Gullberg, M. (2008). Global regulation 
of the interphase microtubule system by abundantly expressed Op18/stathmin. 
Molecular biology of the cell 19, 2897-2906. 
67. Song, B., Liu, X.S., and Liu, X. (2012). Polo-like kinase 1 (Plk1): an Unexpected 
Player in DNA Replication. Cell division 7, 3. 
68. Soung, N.K., Park, J.E., Yu, L.R., Lee, K.H., Lee, J.M., Bang, J.K., Veenstra, T.D., 
Rhee, K., and Lee, K.S. (2009). Plk1-dependent and -independent roles of an ODF2 
splice variant, hCenexin1, at the centrosome of somatic cells. Developmental cell 16, 
539-550. 
69.  Steegmaier, M., Hoffmann, M., Baum, A., Lenart, P., Petronczki, M., Krssak, M., 
Gurtler, U., Garin-Chesa, P., Lieb, S., Quant, J., Grauert, M., Adolf, G.R., Kraut, N., 
Peters, J.M., and Rettig, W.J. (2007). BI 2536, a potent and selective inhibitor of   
70. Toya, M., Terasawa, M., Nagata, K., Iida, Y., and Sugimoto, A. (2011). A kinase-
independent role for Aurora A in the assembly of mitotic spindle microtubules in 
Caenorhabditis elegans embryos. Nature cell biology 13, 708-714. 
71.  Trunnell, N.B., Poon, A.C., Kim, S.Y., and Ferrell, J.E., Jr. (2011). Ultrasensitivity 
in the Regulation of Cdc25C by Cdk1. Molecular cell 41, 263-274. 
72.  Tsvetkov, L., and Stern, D.F. (2005). Phosphorylation of Plk1 at S137 and T210 is 
inhibited in response to DNA damage. Cell Cycle 4, 166-171. 
73.  Van Horn, R.D., Chu, S., Fan, L., Yin, T., Du, J., Beckmann, R., Mader, M., Zhu, G., 
Toth, J., Blanchard, K., and Ye, X.S. (2010). Cdk1 activity is required for mitotic 
activation of aurora A during G2/M transition of human cells. The Journal of 
biological chemistry 285, 21849-21857. 
74. Wang, R., Dong, K., Lin, F., Wang, X., Gao, P., Wei, S.H., Cheng, S.Y., and Zhang, 
H.Z. (2007). Inhibiting proliferation and enhancing chemosensitivity to taxanes in 
osteosarcoma cells by RNA interference-mediated downregulation of stathmin 
expression. Mol Med 13, 567-575. 
 55 
75.  Xu, D., and Dai, W. (2011). The function of mammalian Polo-like kinase 1 in 
microtubule nucleation. Proceedings of the National Academy of Sciences of the 
United States of America 108, 11301-11302. 
76.  Yuan, H., Wang, Z., Zhang, H., Roth, M., Bhatia, R., and Chen, W.Y. (2012). 
Overcoming CML acquired resistance by specific inhibition of Aurora A kinase in the 
KCL-22 cell model. Carcinogenesis 33, 285-293. 
77.  Zhang, H.Z., Wang, Y., Gao, P., Lin, F., Liu, L., Yu, B., Ren, J.H., Zhao, H., and 
Wang, R. (2006). Silencing stathmin gene expression by survivin promoter-driven 
siRNA vector to reverse malignant phenotype of tumor cells. Cancer biology & 
therapy 5, 1457-1461. 
78. Zou, J., Luo, S.D., Wei, Y.Q., and Yang, S.Y. (2011). Integrated computational 
model of cell cycle and checkpoint reveals different essential roles of Aurora-A and 
Plk1 in mitotic entry. Molecular bioSystems 7, 169-179. 
 
  
 56 
 
Figure 2.1: Active Aurora A at the centrosome is reduced in stathmin-depleted Hela 
cells. (A) Outline of AURKA and Plk1 activation of CDC25 and/or CDK1 at mitotic 
entry and feedback between these proteins (reviewed in Lindqvist et al. 2009). (B) 
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Stathmin level was reduced by ~ 75% by siRNA compared to siGLO-transfected control 
cells. Western blot for stathmin, reprobed for tubulin as a loading control. See also 
(Carney and Cassimeris 2010, Carney et al., 2012). Lysates were isolated 48 hr after 
transfection, but depletion was equally evident at 24 hr. (C) Western blot for total 
AURKA protein, reprobed for GAPDH as a loading control. Neither stathmin depletion, 
nor p53 expression, changed AURKA expression (see Supplemental Figure 2 for p53 
restoration by depletion of HPV protein E6).  (D) Box plot of the relative fluorescence 
intensity of total AURKA at the centrosomes of prophase cells measured from 
immunofluorescent images. (E) Representative images of maximum intensity projections 
of Z-stacks of active Aurora A at prophase centrosomes. Fixed cells were stained with an 
antibody against Aurora A phospho-T288 (green in merged images) and propidium 
iodide to stain DNA (red in merged images). (F) Box plot of the relative fluorescence 
intensity of active AURKA (T288P) at the centrosomes of prophase cells measured from 
immunofluorescent images. For (D and F) images were analyzed for fluorescence 
staining intensity as described in Methods. Values for each cell were normalized to the 
average of control cells and statistical significance determined using a student’s t-test. 
Plots represent normalized data pooled from three independent experiments, at least 7 
cells per treatment/experiment. * * denotes p<0.01.  
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Figure 2.2: Stathmin depletion from Hela cells decreased the level of active CDC25. 
Hela cells were transfected with siGlo control siRNA, or siRNA targeting stathmin 
mRNA. Cells were fixed at 48 hours post transfection and stained with an antibody 
recognizing active CDC25 (T48P) (green in merged images) and propidium iodide to 
stain DNA (red in merged images). (A) Representative images of maximum intensity 
projections of Z-stacks of active CD25 (T48P) at mitotic entry. Images were analyzed for 
fluorescence intensity of CDC25 staining. (B) Box plot of relative fluorescence 
intensities of active CDC25. Values for each cell were normalized to the average of 
control cells and statistical significance determined using Student’s t-test. Data shown 
was pooled from two independent experiments, at least 7 cells per treatment/experiment. 
* * denotes p<0.01.  
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Figure 2.3: P53 was restored by depletion of HPV E6 protein from Hela cells. 
Western blot depicts p53 protein level, reprobed for GAPDH as a loading control. 
Doxorubicin treatment was included in one sample to induce p53 stability, increasing 
detectability by blot (see also Carney and Cassimeris, 2010). A sample unrelated to this 
experiment was cropped from the blots. The position of the removed lane is shown as a 
vertical white line. 
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Figure 2.4: Inhibition of AURKA does not delay mitotic entry. (A) Hela cells were 
treated for 16 hours with either DMSO as the vehicle control or AURKA inhibitor, S 
1451 (300 nM). Cells were fixed and stained with an antibody to AURKA phosphor-
T288 and fluorescence intensity of centrosomal AURKA T288P measured as described 
in Methods.  AURKA inhibition decreased active AURKA by ~50%.  Values for each 
cell were normalized to the average value of DMSO-treated cells to allow pooling of 
independent experiments. Statistical significance was determined using Student’s t-test. 
Box plot represents normalized data pooled from two independent experiments, at least 7 
cells per treatment/experiment. (B, C) Hela cells treated with DMSO or S 1451 (300 nM) 
were followed by live cell imaging. Cell fates were determined from phase contrast 
image series as described in Methods. Box plots are shown, summarizing data from >100 
cells and three independent experiments per condition. (B) S 1451 shortened interphase 
by 0.7 h. (C) S 1451 increased mitotic duration compared to DMSO treated controls. ** 
denotes P<0.01 
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Figure 2.5: Active Plk1 on chromatin is decreased in stathmin-depleted cells. Hela 
cells were transfected with siGlo control siRNA, or siRNA targeting stathmin, HPV E6 
or both mRNAs. Cells were either fixed at 48 hours post transfection or whole cell lysates 
were prepared for western blot. (A) Western blot of total Plk1 protein and reprobed with 
GAPDH as a loading control. Restoring p53 by depletion of E6 (see Supplemental Figure 
2) led to decreased expression of Plk1. Stathmin depletion did not effect Plk1 expression. 
(B-D) Fixed cells were stained with an antibody against Plk1 or Plk1 phospho-T210 
(green in merged images) and propidium iodide to stain DNA (red in merged images). 
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Fluorescence intensities were measured and normalized as described in Methods. (B) Box 
plot of Plk1 levels within the nucleus of prophase cells. (C) Representative images of 
maximum intensity projections of active Plk1 (T210P) in prophase cells. Staining 
intensity of active Plk1 is reduced in cells depleted of stathmin, E6, or both proteins. (D) 
Quantitation of active Plk1 (T210P) measured as described in Methods. Depletion of 
stathmin, E6 or both proteins reduced the level of active Plk1 on chromatin. For cells 
depleted of E6 to restore p53, the decreased level of active Plk1 is likely a consequence 
of reduced Plk1 expression. For graphs in B and D, data pooled from three independent 
experiments, at least 7 cells per treatment/experiment. * * denotes p<0.01. (E) Western 
blot of Plk1 (T210P) protein reprobed with GAPDH as a loading control. Plk1 (T210P) 
level is decreased ~50% by stathmin depletion.  
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Figure 2.6:  Partial inhibition of both AURKA and Plk1 delays mitotic entry.  (A,B) 
Hela cells were treated with DMSO as vehicle control or chemical inhibitor 0.8 nM BI 
2536 followed by live cell imaging. Cell fates were determined from phase contrast 
image series as described in Material and Methods section. Box plots are shown, 
summarizing data from >100 cells and three independent experiments per condition. BI 
2536 increased interphase duration by 2.6 h (A) and mitotic duration (B) compared to 
DMSO-treated cells. * denotes p<0.05, *** denotes p<0.001 (C-D) Hela cells 
untransfected, or transfected with non-targeting or siRNA targeting stathmin mRNA and 
synchronized by a double thymidine block were released into media containing DMSO, 
BI 2536 (0.8 nM) or BI 2536 (0.8 nM) and S 1451 (300 nM). Mitotic index was 
determined from propidium iodide stained cells fixed at 2-hour intervals following 
release. The graphs are representatives from at least two independent experiments with 
>100 cells per treatment group in each replicate. 
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Figure 2.7: MTs are required for AURKA activation. (A) Hela cells were treated with 
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either DMSO or 33 µM nocodazole for 3h and then fixed with PFA and stained with 
antibody against AURKA or phospho-AURKA (T288) (green in merge) and propidium 
iodide to stain DNA (red in merge). Representative images are shown of AURKA and 
AURKA (T288P) in prophase cells, demonstrating that MTs are required for AURKA 
localization and activation at the centrosome. (B) The timing of AURKA recruitment to 
the centrosome is independent of stathmin depletion. Centrosomes staining positive for 
AURKA were counted at times after release from a double thymidine block. Graph is a 
representative from two independent experiments with >100 cells per treatment group in 
each replicate. (C-F) Stathmin-depletion broadens the distribution of AURKA near the 
centrosome. (C) Box plot of the width of AURKA centrosomal staining, measured as 
described in Methods. *** denotes p<0.001. (D) Representative line scans of AURKA 
fluorescence intensity near the centrosome. (E, F) The distribution of g-tubulin is 
unaffected by stathmin depletion. 
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Figure 2.8: MT depolymerization restores active Plk1 in stathmin-depleted cells 
without reversing the delay in Plk1 localization to centrosomes. (A) Approximately 
45 hours after siRNA transfection, Hela cells were incubated with DMSO or 33µM 
nocodazole for 3 hours. Cells were then fixed 3 h later and stained with an antibody 
against Plk1 phospho-T210 (green in merged images) and propidium iodide to stain DNA 
(red in merged images). Representative images of maximum intensity projections of Z-
stacks of active Plk1 were analyzed for fluorescence intensity. Values for each cell were 
normalized to the average of control cells and statistical significant determined using 
Student’s t-test. (B) Box plot represents normalized data pooled from three independent 
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experiments, at least 7 cells per treatment/experiment. MT depolymerization restored 
active Plk1 level to nearly that measured in siGLO control-transfected cells *** denotes 
p<0.001. (B) The reduction in active Plk1 measured within nuclei of stathmin-depleted 
cells does not result from a failure to localize to the nucleus. The ratio of fluorescence 
intensities for active Plk1 in the nucleus/cytoplasm were unchanged by stathmin 
depletion. (C) Stathmin depletion delays Plk1 localization to the centrosome. Cells were 
stained with antibodies to Plk1 and g-tubulin at times after release from a double 
thymidine block and the percent Plk1 positive centrosomes are shown. (D) MT 
depolymerization with 33 µM nocodazole did not restore the timing of Plk1 recruitment 
to the centrosome in stathmin-depleted cells. Cells were fixed 9 and 12 h after release 
from a double thymidine block. Data shown are the average of two experiments and > 
100 cells per time point, per experiment. 
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Figure 2.9: Stathmin overexpression decreased Plk1, but not AURKA, activation 
level.  Hela cells were transfected with non-targeting control siRNA, or siRNA targeting 
5’ UTR of stathmin, and/or plasmid containing stathmin-CFP. Fixed cells were stained 
with propidium iodide to stain DNA  and antibodies against either AURKA phospho-
T288 or PLK1 phospho-T210. For stathmin-CFP transfected cells, only those cells 
expressing CFP were used for imaging and analysis. (A) Western blot demonstrating 
stathmin knockdown with the 5'UTR-targeted sequence. (B) Western blot of stathmin 
and/or stathmin-CFP expression as noted.  (C) Box plot of the relative fluorescence 
intensity of AURKA (T288P) at the centrosomes of cells entering mitosis.  (D) Box plot 
of Plk1 (T210P) levels within the nucleus of prophase cells. Values for each cell were 
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normalized to the average of control cells and statistical significance determined using 
Student’s t-test. Box plot represents normalized data pooled from two independent 
experiments, at least 7 cells per treatment/experiment.  * denotes p<0.05, *** denotes, 
p<0.001. 
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Figure 2.11: Stathmin is phosphorylated by AURKA and inhibits Plk1 
autophosphorylation in vitro.  Bacterially-expressed and purified stathmin-FLAG or 
mutants (also FLAG-tagged) were incubated with active AURKA and [32P]-ATP as 
described in Methods. (A) PhosphorImager scan showing phosphorylation of stathmin. 
AURKA was also capable of autophosphorylation. The lesser AURKA 
autophosphorylation in the sample containing stathmin was not consistently observed. 
(B) AURKA phosphorylation was abolished by mutation of S16 and S63 to alanine. 
Histone H3 (H3) served as a positive control for kinase activity.  CB, Coomassie Blue. 
(C) Stathmin was not phosphorylated by Plk1 in vitro, but stathmin significantly reduced 
Plk1 autophosphorylation. (D) Stathmin inhibits Plk1 autophosphorylation in a dose 
dependent manner. The molar ratio of stathmin to Plk1 is given below each lane. 
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Figure 2.12: Summary of MT and stathmin regulation of AURKA and Plk1 
activation.  (A, B) Schematic representations of active AURKA and Plk1 after 
manipulation of MTs (A) and stathmin level (B). Note that stathmin level is diagrammed 
from high to low (left to right). A delay in mitotic entry is only observed when both 
AURKA and Plk1 are inhibited, which is only present in stathmin-depleted cells. (C) 
Outline of where MTs and stathmin MTs interact with enzymes driving mitotic entry. 
Arrows represent direct activation, the line connecting MTs and AURKA represents the 
MT requirement for AURKA localization to centrosomes, the dashed line between MTs 
and Plk1 represents the ability of MT depolymerization to restore Plk1 activity after 
stathmin depletion. 
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Figure 2.10: Exogenous stathmin expression restores normal MT number and mitotic 
entry timing.  Hela cells were transfected with non-targeting control siRNA, or siRNA 
targeting 5’ UTR of stathmin, and/or plasmid containing stathmin-CFP or STMN-GFP. 
(A) Representative images of MTs are shown for depletion and/or expression of stathmin 
(STMN) tagged with GFP or CFP. (B) MT numbers were counted for all detectable ends 
within 5 µm of the cell periphery and reported as MTs per µm of cell circumference. Box 
plot represents pooled data from 4 independent experiments with at least 19 cells per 
treatment.  (C-D) Percent of cells staining positive for (C)CDK1 (Y15P) or (D) TPX2.  * 
, **, *** denotes p<0.05, p<0.01 and p<0.001 respectively.  
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Chapter 3 
 
Mechanistic basis for p53-deficient cell death triggered by a mitotic entry delay.  
 
Introduction  
 
 Mutations or loss of the tumor suppressor gene, p53, are the most prevalent and 
catastrophic gene alterations in cancer, present in over half of all human cancers (Soussi 
2006, Green and Kroemer 2009). P53 acts as a master regulator in normal cells, 
facilitating responses to stress and DNA damage, cell cycle progression, metabolism and 
mitochondrial integrity (Green and Kroemer 2009, Matoba 2006, Nantajit 2010). Great 
efforts have been made to restore p53 function in cancer cells by viral delivery of WT 
p53, inhibition of nonsense mediated RNA decay to promote read through of premature 
stop codons or small molecule inhibition of mutant copies of p53. However, such 
therapies have yet to successfully make it out of clinical trials in the U.S. (Vecil and Lang 
2003, Prabhu 2012, Martin 2014).   
  In addition to restoring p53 function, there has also been much research toward 
finding selective targets for cells with missing or mutated p53.  Indeed p53-deficient cells 
are more vulnerable to ATR/Chk1 inhibition with DNA damage, serine/threonine kinase 
inhibition as well as PLK1 inhibition (Reaper 2011, Schoppy and Brown 2012, Jemaa 
2012, Liu 2006, Sur et al.2008).  However, these treatments, despite favoring p53 
deficient cells, still lead to significant cell death in non-transformed cells.   
 A microtubule regulator, stathmin, is overexpressed in a number of cancers and 
thus represents a potential therapeutic target (Mistry 2005, Belletti 2011). Stathmin acts 
as a microtubule destabilizer by binding soluble tubulin dimers and promoting 
catastrophe of existing microtubules.  Depletion of stathmin slows proliferation and 
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increase cell death in cancer-derived cell lines (Mistry 2005, Zhang 2006, Wang, 2007) 
and in some studies death was observed only in p53 deficient cells (Alli 2002, Alli 2007, 
Carney and Cassimeris 2010). The effect of stathmin loss on proliferation occurs at least 
in part via changes in microtubule dynamics that delay mitotic entry by slowing the 
kinetics of CDK1 activation (Carney et al. 2012, Silva and Cassimeris 2013).   
 However, the mechanism by which stathmin loss leads to cell death is unknown.  
We set out to determine whether cell death in stathmin-depleted cells was directly 
triggered by a mitotic entry delay, by some other consequence of altered microtubule 
stability or the result of a novel function of stathmin loss.  Additionally, we wanted to 
identify the role p53 plays in survival for these cells.  Here we describe results 
demonstrating that a mitotic entry delay triggers caspase 8 dependent apoptosis 
selectively in cells without functional p53. Caspase 8 activation is inhibited by cFLIP, a 
protein that can form heterodimers with procaspase 8 and is normally present in low 
levels in p53 deficient cells. We find that restoration of cFLIP level rescues viability of 
stathmin-depleted p53 deficient cells.  These findings reinforce the potential of stathmin 
modulation as a therapeutic strategy and suggest that mitotic entry disruption can 
selectively cause cell death in the majority of cancers lacking a functional p53 protein.   
 
Results: 
A 4 hour G2 delay is sufficient to induce cell death in p53-deficient cells  
 To determine if a mitotic entry delay was initiating death in stathmin-depleted 
cells, we induced a mitotic entry delay using a combination of enzyme inhibitors.  We 
had previously found (Silva and Cassimeris, 2013) that stathmin depletion reduces the 
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activity of mitotic entry kinases, AURKA and PLK1, slowing kinetics of CDK1 
activation to produce an approximate four hour delay in mitotic entry (Silva and 
Cassimeris 2013).  We used a combination of chemical inhibitors to both AURKA 
(inhibitor S1451) and PLK1 (inhibitor BI2536) to delay mitotic entry in Hela cells first 
synchronized with a double thymidine block.  Approximately 6 hours following release 
from the block, we added either a combination of S1451 and BI2536 or DMSO as a 
vehicle control for four hours and then replaced drug-containing medium with regular 
DMEM.  The cells were then followed over the next 72 hours via live cell imaging.  
From these videos we determined the percent of cells that died. Cell death was marked by 
cell retraction and formation of apoptotic bodies (Figure 3.1, A).  We found that the 
group of cells treated with both AURKA and PLK1 inhibitors had a three fold increase in 
cell death over DMSO treated control cells and these increases were statistically 
significant (Figure 3.1, B).  In order to know whether cell death occurs during a distinct 
point after a mitotic entry delay or at a particular stage of the cell cycle, we also tracked 
when cell death occurred respective to both start of imaging and from that cell's last 
mitosis. We observed that cells die anywhere from hours to days following an initial 
mitotic entry delay and that death can occur at any point of the cell cycle (Figure 3.1 C).   
 To confirm that the cell death was due to a delay in mitotic entry and not some off 
target effect of AURKA and PLK1 inhibition, we repeated these experiments using a 
CDK1 inhibitor (RO3306) at a concentration (10uM) sufficient to arrest cells in G2.  We 
also found that cell death in the group treated with the CDK1 inhibitor for 4 hours was 
significantly higher than DMSO controls, a four-fold increase (Figure 3.1, B). 
Additionally, we confirmed that the increase in cell death was due to inhibition of CDK1 
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specifically prior to mitotic entry and not elsewhere in the cell cycle.  We treated 
asynchronously growing Hela or HCT116 p53 -/- cells with CDK1 inhibitor (RO3306) for 
four hours and assessed viability 48 hours following treatment by trypan blue exclusion 
(Figure 3.1, D). We found no increase in cell death over DMSO treated controls 
indicating that CDK1 inhibition only prior to mitotic entry causes cell death. 
 Since it was previously shown that stathmin depletion leads to death only in cells 
lacking p53 (Alli et al. Oncogene 2007, Carney and Cassimeris 2010), we next asked 
whether the death induced by a 4 hour delay in mitotic entry was also dependent on the 
absence of p53. Using isogenic colorectal cancer cell lines differing in p53 genotype, 
HCT116 p53+/+ and p53 -/- , we synchronized cells with a double thymidine block and 
pulsed with either DMSO or 10uM RO3306 for four hours beginning 6 hours after 
release from the block.  At 48 hours after drug pulse, a time at which we observed the 
most death in the time-lapse imaging experiments, we assayed viability by a trypan blue 
exclusion assay.  We found that only the HCT116 p53 -/- line pulsed with RO3306 
exhibited a significant decrease in viability compared to DMSO pulsed control cells 
(Figure 3.1, E). We previously used these cell lines to confirm the p53 dependence for 
stathmin depletion induced death (Carney and Cassimeris, 2010). 
 Given that the percent of cells that die from stathmin depletion is greater than a 
single 4 hour delay produces, it was possible that stathmin depletion causes some other 
effect outside of mitotic entry that also contributes to cell death. To test whether stathmin 
depletion induces cell death by delaying mitotic entry or by a mechanism independent of 
the cell cycle delay, we next compensated for reduced AURKA and PLK1 in these cells 
to eliminate the delay in G2 by inhibiting Wee 1 kinase. Since Wee1 normally inhibits 
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CDK1 activation, we hypothesized that inhibition of Wee1 would alleviate the mitotic 
entry delay in stathmin-depleted cells. To test this hypothesis we synchronized control 
and stathmin-depleted Hela cells with a double thymidine block and released cells into a 
Wee1 inhibitor (10nM MK1775) or DMSO.  Mitotic index was determined at timepoints 
following release for all groups. For stathmin depletion, Hela cells were transfected with 
siRNA targeting stathmin, which reduces stathmin protein levels to approximately 25% 
of control cells (Silva and Cassimeris, 2013, Carney et al. 2013, Carney and Cassimeris, 
2010; See Chapter 2).  We observed that stathmin-depleted cells treated with MK1775 
entered mitosis with normal timing following release from a thymidine block (Figure 3.2, 
A).   
 Since Wee 1 inhibition restores normal mitotic entry timing in stathmin-depleted 
cells, we were able to assess whether reduced stathmin level could induce death in the 
absence of a cell cycle delay.  We synchronized control and stathmin-depleted Hela cells 
released into either MK1775 or DMSO and measured cell viability 48 hours following 
release. We found that Wee 1 inhibition restored viability in stathmin-depleted cells to 
that of control cells indicating that the mitotic entry delay from stathmin depletion is the 
major trigger of cell death (Figure 3.2, B). Given that we observed cell death occurring at 
various times following a mitotic entry delay from treatment with AURKA and PLK1 
inhibitors, we wanted to know if stathmin-depleted cells also die randomly.  Using live 
cell imaging we followed stathmin-depleted Hela cells for 72 hours and tracked when 
these cells die respective to their last mitosis.  We found that similar to treatment with 
AURKA and PLK1 inhibitors, there is no apparent pattern to when death occurs (Figure 
3.2, C). Microtubule targeting drugs that block cells in mitosis also have a similar 
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phenotype, where many cells die at various times after slipping out of the mitotic arrest 
(Gascoigne and Taylor, 2009).  
 
Mitotic Entry Delay induced death is caspase 8 dependent 
 Since a mitotic entry delay is sufficient to trigger cell death, we then wanted to 
know by what mechanism cell death occurs. We had previously determined that 
stathmin-depleted cells were undergoing apoptotic cell death based on cell morphology 
changes, caspase 3 activation and the presence of cleaved PARP (Carney and Cassimeris, 
2010). We then asked which apoptotic pathway(s) were activated in these cells. We had 
hypothesized that cell death from stathmin depletion was occurring via the intrinsic death 
pathway and caspase 9 activation since others have found that prolonged CDK1 activity 
during mitotic arrest leads to caspase 9 dependent death. Cell lysates from stathmin-
depleted and non-targeting siRNA transfected control cells were prepared on days 2-5 
following transfection and probed for (active) cleaved Caspase 8 and (active) cleaved 
Caspase 9 via western blot.  Initially, we did not detect an increase in either form of 
active caspase.  Since the observed death in these cells is modest and the time frame from 
initiator caspase cleavage to cell death is on the order of minutes (Green, 2005), we 
repeated the experiment with the addition of z-VAD, a broad caspase inhibitor, to allow 
accumulation of active caspases. Since caspase 8 and 9 are initiator caspases, z-VAD 
would bind these caspases as soon as they were active thereby stopping the death cascade 
and allowing accumulation of active initiator caspases. Stathmin-depleted Hela cells 
treated with z-VAD had an increased amount of cleaved caspase 8 compared to control 
cells treated with z-VAD (Figure 3.3, A) whereas there was no detectable activation of 
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caspase 9 (data not shown).  We also detected increased cleaved caspase 8 in both Hela 
cells and HCT116 p53 -/- cells delayed for 4 hours at mitotic entry with CDK1 inhibitor, 
RO3306 (Figure 3.3, A and B).  
  To confirm that caspase 8 activation was triggering cell death, we blocked 
caspase 8 activity with a specific caspase 8 inhibitor, Z-IETD.  We treated Hela and HCT 
-/- p53 cells with 4 hour pulses of RO3306 or DMSO as described above and then added 
either Z-IETD or DMSO for 48 hours and measured viability. We found that in both cell 
lines, treatment of RO3306 pulsed cells with Z-IETD restored viability to that of control 
cells, confirming the requirement for caspase 8 activity to activate a death pathway 
following a mitotic entry delay (Figure 3.3, C and D).  Consistent with caspase 8 
activation, we also observed an increase in active (active) NFκB and active ERK, which 
are downstream targets of caspase 8 activity (Figure 3.3, E and F). 
   Programmed cell death can also be driven by caspase 8 activity via interaction 
with stress induced adaptor kinase RIP1, a mechanism called necroptosis (Festjens 2007, 
Tenev 2011).  We probed whether a RIP1 inhibitor, necrostatin, could alleviate cell death 
following stathmin-depletion.  We added necrostatin (1uM) at a concentration that is 
double the recommended IC50 (EMD Millipore) to stathmin-depleted Hela cells for 72 
hours following transfection and observed no rescue in cell viability (data not shown).  
From these data we conclude that stathmin depletion, via a mitotic entry delay, leads to 
caspase 8 dependent cell death that is likely apoptosis and not necroptosis.  
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CDK1 inhibition decreased caspase 8 phosphorylation 
 A key modulator of apoptosis inhibition during mitosis is CDK1 activity.  CDK1 
has been shown to phosphorylate a number of caspases, including caspase 8 (Andersen 
2009, Matthess 2010).  Phosphorylation by CDK1 on caspases at or near interdomain 
sites prevents caspase activation (Andersen, 2009).  Since caspase 8 has been shown to be 
a substrate for CDK1, we hypothesized that decreased CDK1 activity as seen in stathmin-
depleted cells would be accompanied by a decrease in procaspase 8 phosphorylation at 
Serine 387 (Ser387P), which protects against caspase 8 autoproteolysis (Matthess 2010).  
We probed lysates of Hela cells via western blot and found procaspase 8 (S387P) to be 
greatly reduced after either stathmin depletion or CDK1 inhibitor treatment (Figure 3.4, 
A and B).  
 
cFLIP level is dependent on p53  
 Given that cell death is only observed following stathmin depletion or a mitotic 
entry delay in cells lacking p53,we hypothesized that it is likely that a regulator of 
caspase 8 is influenced by p53 status. A strong candidate protein is cFLIP, an endogenous 
caspase 8 inhibitor, whose expression or protein stability requires p53 (Fukazawa 2010, 
Galligan 2005). We hypothesized that cFLIP levels were reduced in p53 deficient cells. 
We probed cFLIP levels in Hela cell lysates depleted of stathmin and/or HPV protein E6 
to restore p53 (see Carney and Cassimeris 2010, Figure 3.4, C).  We found that restoring 
p53 greatly increased cFLIP protein levels and surprisingly, stathmin depletion alone 
further reduced already low levels of cFLIP in Hela cells (Figure 3.4, D).  In order to 
know whether decreased cFLIP in stathmin-depleted cells was contributing to caspase 8 
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activation and therefore cell death, we restored cellular cFLIP levels by transient 
expression of FLAG tagged cFLIP (Figure 3.4, E).  As others have reported (Chang 
2002), cells are sensitive to both lower and higher levels of cFLIP and we found that our 
typical transfection protocol using 1ug plasmid DNA lead to high level over-expression 
of FLAG-cFLIP which on its own induced cell death.  Transfection with a lower plasmid 
amount, 100ng, did not induce cell death and was sufficient to restore viability in 
stathmin-depleted to the level of control cells (Figure 3.4, F).  
 
Discussion: 
 The requirement for stathmin in survival of cancer cells lacking p53 has been 
poorly understood.  It was known that stathmin depletion leads to mitotic entry delay as 
well as cell death, but whether these two phenotypes were linked was unknown.  Here we 
set out to determine if a mitotic entry delay initiates cell death and by what mechanism 
cell death occurs.  We established that a four hour delay in mitotic entry triggers cell 
death via caspase 8 activation. However, the possibility of caspase 9 involvement in 
mitotic entry delay induced apoptosis cannot be ruled out.  Caspase 8 is known to trigger 
cytochrome C release and therefore downstream apoptosome formation and caspase 9 
activation (Kruidering and Evan 2000).  The time from caspase 9 activation to cell death 
occurs on the order of minutes (Green, 2005).  Considering the potentially small time 
window of caspase 9 activity and the random timing of individual cell death, it is possible 
that increases in cleaved caspase 9 are too small to detect.  However, if there is a role for 
caspase 9, it would be occurring downstream of caspase 8 activation.   
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 In order to know why a mitotic entry delay contributes to caspase 8 activity, we 
considered the biochemical differences between a delayed and normal mitotic entry 
timing and how these differences relate to what is known about how cells survive a 
prolonged mitosis (a delay in mitotic exit). For example, it is proposed that during 
mitosis, cells require increased protection against cell death because factors such as loss 
of adhesion signaling or leakage of cytochrome c during mitochondrial fission (Andersen 
2009) make mitotic cells particularly vulnerable to activation of apoptosis. CDK1 is a key 
mediator of this protection, phosphorylating a number of caspases to inhibit their 
activation. During a mitotic entry delay, such as that induced by stathmin depletion, 
CDK1 activity remains below threshold for an atypically long duration, estimated to be at 
or greater than four hours. These data are consistent with a model where decreased CDK1 
activity during prolonged mitotic entry leads to loss of protective phosphorylation of 
caspase 8 and lowers the threshold for caspase 8 activation, which may make these cells 
more vulnerable to apoptotic stimuli.  
 In order to know if phosphorylation of Ser387 on caspase 8 actually confers 
resistance to apoptosis, we expressed a pseudophosphorylated form of caspase 8, with 
Ser387 mutated to Glutamic Acid (S387E) with the hypothesis that it might act as a 
dominant negative form of caspase 8 in cells.  Expression of S387E did not increase 
viability of stathmin-depleted cells (data not shown).  It is possible that the phospho-
mimetic mutant of caspase 8 does not act as a dominant negative version of the caspase 
or that there is already sufficient endogenous caspase 8 concentration for activation.  
Therefore, the functional significance of phospho-Ser387 on caspase 8 is still unknown.   
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 Since a mitotic entry delay only activates caspase 8 in the absence of p53, we 
hypothesized that caspase 8 inhibitor is regulated by p53. We measured levels of a known 
caspase 8 inhibitor, cFLIP, and found it to be reduced in the absence of p53 (Figure 3.4, 
D), consistent with previously published results (Bartke 2001).  Based on these 
observations, we hypothesized that p53 deficient cells are more susceptible to death due 
to decreased levels of cFLIP protein. This hypothesis was supported by experiments to 
over-express cFLIP, which restored viability to stathmin-depleted or mitotic entry 
delayed cells.  Taken together, the combination of CDK1 inhibition and loss of p53 
culminates in loss of two sources of caspase 8 inhibition, phosphorylation of Ser387 on 
caspase 8 and decreased cFLIP levels.  Decreased phosphorylation at Ser387 and lower 
cFLIP levels are potentially sufficient for caspase 8 activation in the absence of any other 
death stimuli.   
 The timing and small percentage of cell death observed in our experiments 
(Figure 3.1,C and Figure 3.2, C) is consistent with the above model. We determined that 
cell death occurs at various times following mitotic exit and therefore in the absence of 
cell cycle specificity, other than an initiating event in G2.  If caspase 8 activation in 
stathmin-depleted, p53-deficient cells were stochastic, cell death would occur randomly 
following an initial mitotic entry delay and this is precisely what we observe. The trigger 
for caspase 8 activation remains unknown, but several possible mechanisms are discussed 
next. 
 It is possible that CDK1 inhibition and decreased cFLIP allow increased caspase 8 
sensitivity to some unknown external death signal, produced in response to cell stress 
caused by a mitotic entry delay. Alternatively, an intracellular trigger may promote 
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assembly of a caspase 8 activating platform, such as the Ripoptosome (Tenev 2011) 
without requiring engagement of a death receptor.  In either case, we expect that the 
normal balance between pathways that activate and inhibit caspase 8 activation are 
altered to favor activation. Understanding the trigger mechanism will be difficult given 
its transient and stochastic formation.  
 Regardless of the death-triggering mechanism, it is clear that p53 deficient cells, 
because of decreased cFLIP levels, are more vulnerable to caspase 8 activation. 
Disrupting mitotic entry is an attractive therapeutic strategy since normal cells do not 
appear to be effected by a small delay such as that achieved by partial PLK1 and 
AURKA inhibition. Stathmin inhibition, either via small molecules or RNA interference, 
would be an ideal means to delay mitotic entry without disrupting normal mitotic 
progression.  Avoiding abnormal mitosis would alleviate some of the harmful effects, 
such as aneuploidy and massive cell death in normal tissues, caused by microtubule 
disrupting agents. (Gascoigne and Taylor 2009).  Most importantly stathmin inhibition 
and slowing of mitotic entry represents the only treatment known thus far to selectively 
cause death only in p53 deficient cells.   
 
Materials and Methods: 
Cell Culture and Plasmid Transfections:  Hela and HCT 116 (p53 +/+ and p53 -/-  lines 
(gift of Dr. Volgelstein, Johns Hopkins School of Medicine) cells were grown in DMEM 
(Sigma) supplemented with 10% fetal bovine serum (FBS; Invitogen) and 1X 
antibiotic/antimycotic (Sigma). In some experiments, cells were synchronized through a 
double thymidine block by overnight incubation in 5mM thymidine (in DMEM), 8 h 
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release in DMEM after 5 washes in warm PBS and then 16 h incubation in 5mM 
thymidine (in DMEM). Cells were transferred to DMEM following 5 washes with warm 
PBS and used for Trypan Blue exclusion assays and/or cell lysate preparation 48-72 
hours following release. 
  In some experiments Hela cells were transfected with plasmids for expression of 
FLAG-tagged-cFLIP or an empty vector encoding FLAG, or an empty vector encoding 
GFP using X-tremeGene HP DNA Transfection Reagent (version 1.0; Roche 
Diagnostics, Indianapolis, IN) according to the manufacturer’s protocol. Cells were 
transfected approximately four hours following siRNA transfections and cell viability 
was assessed approximately 48 hours following initial transfection.    
 
Indirect Immunofluorescence and confocal microscopy: Hela cells were grown on 
glass coverslips and treated as described above. They were either fixed with 4% 
Paraformaldehyde/20% glycerol in PBS, pH 7.3 (PFA, Electron Microscopy Services) for 
10 minutes at room temperature or with methanol supplemented with 1mM EDTA at -
20oC for 10 minutes. Cells fixed with PFA were permeabilized with methanol at -20oC 
for 10 minutes. Fixed cells were incubated with blocking reagent (10% FBS in phosphate 
buffered saline, PBS) for 30 minutes at 37oC followed by a 45 minute incubation with 
primary antibody at 37oC. Cells were then washed with PBS and incubated with 
secondary antibody and 1.5 µM propidium iodide for an additional 45 minutes at 37oC. 
Antibodies used included: anti-phospho NFkB (Ser536)(1:1000, Cell Signaling), anti-
NFkB (T288) (1:1000, Cell Signaling), anti-phospho-ERK 1/2 (Thr218Tyr220) (1:1000, 
Cell Signaling), anti-ERK (1:100, Cell Signaling), and Goat anti-mouse or anti-rabbit 
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Alexa Fluor 488 (1:50, Invitrogen). Coverslips were then washed with PBS and mounted 
on slides with Vectashield (Vector Labs). Cells were imaged as described previously 
(Piehl and Cassimeris, 2003) using 63X/1.4 numerical aperture plan apo objective on an 
inverted microscope (Zeiss Axiovert 200M). For synchronized cells mitotic index was 
determined by staining with propidium iodide and counting cells with condensed 
chromatin as a percent of total cells. At least ten fields (coverslip positions, > 100 cells 
per time point) were counted for each treatment group for each independent experiment. 
 
Drugs and Reagents:  Chemical inhibitors to PLK1 (BI 2536, Grinshtein et al,. 2011), 
AURKA (S 1451, Yuan et al., 2011), and Wee1 ( MK1775, Hirai et al, 2009) were 
purchased from Selleckchem.  Chemical inhibitor to CDK1 (Vassilev 2006) and pan-
caspase inhibitor, Z-VAD-FMK were purchased from Tocris Bioscience.  Caspase 8 
specific inhibitor, Z-IETD was purchased from Millipore.   All other reagents were from 
Sigma unless noted otherwise.  
 
RNA Interference and Transient Transfection:  Cells were grown in 35mm dishes and 
transfected with siRNAs 1-2 days after plating using GeneSilencer (Genlantis) according 
to the manufacturer’s protocol. Cells were serum starved from the time of transfection to 
four hours post-transfection to improve efficiency. siRNA oligonucleotides 
(Thermoscientific/Dharmacon) used were SMTN1 (Op18-443), 5’- 
CGUUUGCGAGAGAAGGAUAdtdt-3’.  siGenome non-targeting siRNA 
(Thermoscientific/Dharmacon) was used as control siRNA sequences for these 
experiments (Silva and Cassimeris 2013, Carney et al. 2012).  
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Western Blotting: Soluble cell extracts were prepared as described previously (Carney 
and Cassimeris, 2010) and protein concentrations were measured by Bradford assay. 
Lysates were diluted in PAGE sample buffer, 40 µg total protein per lane was typically 
loaded and resolved in 10% polyacrylamide gels and transferred to Immobilon 
Membranes (Millpore, Billerica, MA). Membranes were blocked with 5% non-fat milk or 
5% BSA (depending on manufacturer recommendation) in Tris-buffered saline with 0.1% 
Tween and then probed with primary antibodies: anti cleaved Caspase 8 (1:1000; Cell 
Signaling), phospho-Caspase 8 (1:1000, gift from Klaus Strebhardt, J.W. Goethe 
University, Matthess et al. 2010), anti-cleaved Caspase 9 (1:1000;Cell Signaling),  or 
cFLIP ( 1:1000, Cell Signaling),  followed by secondary antibodies, anti-mouse (1:2000; 
Abcam) or anti-rabbit (1:10,000, BD Biosciences) horseradish peroxidase-linked IgG. 
Immunoreactive bands were developed using enhanced chemiluminscence (GE 
Amersham). Membranes were reprobed with anti-α-tubulin (1:1000, Sigma) or GAPDH 
(1:1000, Abcam) as a loading control.  
 
Live Cell Imaging:  To follow cell fates over several days, Hela cells were plated on 
Mattek dishes and imaged using a Nikon Biostation IM as described previously (Silva 
and Cassimeris, 2013; Carney et al., 2012). Cells were imaged with phase contrast optics 
using a 20X objective and images were collected at 5 minute intervals for 24-72 hours. 
Cell fates were tracked from image series. Cell death was determined by changes in cell 
morphology characterized by cell retraction and blebbing of the plasma membrane.  
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Cell Viability Measurements: For synchronization experiments, cells were allowed to 
grow for two days following pulses with kinase inhibitors.  For cells transfected with 
siRNA and/or plasmids, cells were allowed to grow asynchronously for three days 
following transfection.  On the day of measurement, cells were trypsinized and 
resuspended in PBS with 0.2% Trypan Blue and counted using a hemocytometer to 
determine viability via Trypan Blue exclusion.   
 
Data Analysis: Statistical analysis of fluorescence intensity and cell cycle durations were 
performed using unpaired t-tests with GraphPad Software 
(www.graphpad.com/quickcalcs/ttest1.cfm).  
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Figure 3.1: A mitotic entry delay triggers cell death in p53 deficient cells.  Live cell 
recordings of Hela cells synchronized with double thymidine block, released and pulsed 
with DMSO, S1451 and BI2536 or RO3306 for four hours at 6 hours from release. (A) 
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Representative images of a cell undergoing apoptosis following a mitotic entry delay. (B) 
Cells and progeny were followed for 72 hours and percent of total cell death calculated. 
The mitotic entry delay induced by these inhibitors (BI2536 and S1451) increased cell 
death which occurred at various times following each cell's last mitosis (C).  Four hour 
pulse of inhibitors in asynchronous Hela and HCT116 p53-/- cells (D) followed by live 
cell recordings as in (A, B).  Treatment with AURKA and PLK1 or CDK1 inhibitors in 
an asynchronous population does not decrease cell viability, demonstrating that the drugs 
are not toxic throughout the cell cycle.  (E) Synchronized HCT116 p53 +/+ and p53 -/-   
cell lines synchronized and pulsed with RO3306 as in (A).  Viability was assayed 48 
hours post inhibitor treatment via trypan blue exclusion. Mitotic entry delay via CDK1 
inhibition decreased cell viability only in the p53 knockout cell line. Graphs are 
representative of at least three independent experiments with >300 cells/experiment. ** 
denotes p<0.01, *** denotes p<0.001. 
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Figure 3.2: A Wee 1 inhibitor relieved both the stathmin depletion-induced cell cycle 
delay and cell death. Hela cells were synchronized with a double thymidine block and 
transfected with non-targeting siRNA or siRNA to stathmin were released into medium 
containing DMSO or the Wee 1 inhibitor MK1775. (A) Mitotic index was determined at 
2 hour intervals for 12 hours following release. Wee1 inhibition restored mitotic entry 
timing in stathmin-depleted cells to that of control treated cells.  (B) Viability was 
assayed at 48 hours following release via trypan blue exclusion. Relieving the mitotic 
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entry delay in stathmin-depleted cells restored viability to that of control treated cells.    
(C) Timing of cell death from the last mitosis recorded for individual Hela cells depleted 
of stathmin. See Figure 3.1C for similar plot for inhibitor BI2536 and S1451 treated cells. 
Death occurs at variable times following last mitosis.  ** denotes p<0.01 
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Figure 3.3: A mitotic entry delay triggers caspase 8 activation. Western blot for 
cleaved caspase 8, reprobed for tubulin as a loading control. (A, left) Hela cells or (B) 
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HCT116 synchronized with double thymidine block and pulsed with RO3306 for four 
hours upon release or (A, right) transfected with non-targeting or siRNA to stathmin and 
treated with Z-VAD.  Lysates made 48 hours following transfection or inhibitor pulse. 
Stathmin depletion or a pulse of CDK1 inhibitor to lengthen G2 increased the level of 
cleaved caspase 8.  (C, D) Hela cells (C) or HCT116 -/-p53 cells (D) were synchronized 
with a double thymidine block and pulsed with RO3306 for four hours. Following 
RO3306 inhibitor washout, cells were incubated with medium containing DMSO or Z-
IETD for 48 hours and assayed for viability via trypan blue exclusion. Caspase 8 
inhibition with Z-IETD restores viability in RO3306 treated cells.  (E) Representative 
graph of immunofluorescence experiments in stathmin-depleted Hela cells stained for 
NFkB and DNA.  Percent of cells with nuclear NKκB staining was determined. Stathmin 
depletion increased levels of phospho-NFκB consistent with caspase 8 activation. (F) 
Western blot for phospho-ERK, reprobed for GAPDH as a loading control. Lysates from 
Hela cells transfected with non-targeting or siRNA to stathmin. Representative images of 
western blots shown, each experiment was performed at least twice. Graphs are 
representative of at least three independent experiments.  * denotes p<0.05, ** denotes 
p<0.01, *** denotes p<0.001. 
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Figure 3.4: Stathmin depletion and cFLIP regulate caspase 8 activity.  Western blot 
for phospho-caspase 8 (Ser387), reprobed for GAPDH or tubulin as a loading control. 
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Hela cells (A) transfected with non-targeting or siRNA to stathmin or (B) synchronized 
and pulsed with RO3306 for four hours.  Stathmin loss or a pulse of CDK1 inhibitor 
reduced the level of phospho-caspase 8. (C) Western blot for p53. Lysates were prepared 
from Hela cells either untransfected or transfected with siRNA targeting HPV protein E6 
and treated with Doxorubicin (included to stabilize p53) for 6 hours at 42 hours following 
transfection. siRNA knockdown of E6 restores p53 level. (D) Western blot for cFLIP, 
reprobed with GAPDH as a loading control. Hela cells were transfected with non-
targeting siRNA, or siRNA to stathmin and/or E6. Cells lacking p53 have decreased 
cFLIP protein levels compared to Hela cells transfected with E6 to restore endogenous 
p53. Stathmin depletion reduced the cFLIP level relative to control siRNA-transfected 
cells.  (E) Western blots of lysates from Hela cells transfected with FLAG-tagged cFLIP.  
Antibodies to FLAG (top) and cFLIP (bottom) produce bands at 55kDA, the approximate 
molecular weight of cFLIP.  (F) Hela cells were transfected with non-targeting siRNA or 
siRNA to stathmin and a plasmid containing FLAG-tagged cFLIP or empty FLG vector, 
as noted on the plot.  Viability was assayed by trypan blue exclusion at 48 hours 
following transfection.  Exogenous cFLIP expression rescued viability in stathmin-
depleted cells to that of control cells. Representative images of western blots shown, each 
experiment was performed at least twice. Graphs representative of at least three 
independent experiments. * denotes p<0.05. 
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Chapter 4:  Conclusions and Future Directions 
 Future Directions 
 Work described in this dissertation lays out the general mechanism by which 
stathmin depletion leads to a mitotic entry delay that is sufficient to trigger caspase 8 
dependent death selectively in cells lacking p53.  However, further investigation needs to 
be done in order to understand how stathmin, both independently and via microtubules, 
alters AURKA distribution and PLK1 recruitment and activation at centrosomes.  
Additionally, although stathmin-depleted cells undergo a p53 dependent cell death due to 
caspase 8 activity, it is unknown whether caspase 8 activation is the result of some 
unknown death ligand signaling or a stochastic consequence of reduced inhibitors.  The 
following proposed models and experiments would further define the exact pathways and 
mechanisms affected by loss of stathmin and p53.   
 
Stathmin and PLK1 recruitment  
 In Drosophila, PLK1 is found associated with microtubules throughout interphase 
and during cytokinesis.  This recruitment and stable association of PLK1 with 
microtubules was found to be dependent on MAP205, Drosophila homolog to human 
MAP4 (Archambault 2008).  MAP205 tethers PLK1 strongly to microtubules in 
interphase and phosphorylation by CDK1 on MAP205 relieves interaction of PLK1 and 
MAP205 and allows PLK1 to move to centrosomes (Archambault 2008). Stathmin-
depleted cells have increased microtubules and potentially more MAP4 bound which may 
translate into more microtubule bound PLK1, decreasing the pool available to localize to 
centrosomes.  Additionally, decreased CDK1 activity may further inhibit release of 
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tethered PLK1 from MAP4 and microtubules.  This may explain the two-part activation 
scheme for PLK1.  MT depolymerization restores the amount of active PLK1 in prophase 
cells perhaps by untethering Map4 and PLK1 from microtubules.  However, Plk1 
activation may require dissociation of PLK1 from MAP4, which likely still requires 
CDK1 activity.  Our inability to detect PLK1 at centrosomes with normal timing after 
nocodazole treatment may be the result of PLK1/MAP4 interactions that hinder PLK1 
docking at centrosomes.  Alternatively, since MT depolymerization rescues mitotic entry 
timing and restores levels of active PLK1 in prophase cells, it is possible that 
PLK1/MAP4 interactions may mask antibody recognition while still allowing PLK1 
recruitment that was not detectable by immunofluorescence.  This may explain how 
microtubule depolymerization rescues the mitotic entry delay and accumulation of active 
PLK1 around chromatin but not levels of centrosome associated PLK1.   
 To test whether PLK1 is tethered to microtubules in interphase we have looked 
for co-localization of PLK1 with α- tubulin via indirect immunofluorescence.  PLK1 was 
not visible on microtubules in Hela cells using PLK1 and tubulin antibodies. However, 
expression of PLK1-GFP as done by Archambault et al. may reveal co-localization of 
PLK1 on MTs. Using a GFP tagged construct may alleviate issues with masking of 
antibody binding sites and provide a more robust fluorescence signal.  Alternatively, 
microtubule co-pelleting assays may reveal association of PLK1 with polymerized 
tubulin. If this model is correct, stathmin depletion is predicted to increase both Map204 
and PLK1 association with microtubules either via immunofluorescence or co-pelleting 
assay. Furthermore, if MAP4 tethering of PLK1 to MTs inhibits PLK1 centrosomal 
localization,  depletion of MAP4 would rescue the PLK1 activation in stathmin-depleted 
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cells by increasing the cytoplasmic pool of PLK1 available for centrosome recruitment.  
Similarly, over expression of MAP4 would likely mimic PLK1 recruitment defect seen 
with stathmin-depletion.   
 
Stathmin and AURKA Distribution  
 We observe a wider distribution, equivalent to a roughly two-fold increase in 
volume, of total and active AURKA in stathmin-depleted cells.  We hypothesized that a 
wider distribution of AURKA had a dilution effect on the kinase's concentration at the 
centrosome.  Since AURKA needs to dimerize in order to autophosphorylate, a dilution 
of monomers would decrease dimer formation and limit autoactivation, which has been 
demonstrated in vitro (Joukov 2010).  Using known kinetics of AURKA activation from 
computational modeling, a two fold dilution of AURKA concentration is predicted to 
yield a 50% decrease in active kinase which is precisely the decrease in activity measured 
upon stathmin depletion (Zou 2011, Silva and Cassimeris unpublished).  The mechanism 
behind a wider distribution of AURKA is not simply due to a wider distribution of 
gamma-tubulin since that centrosome marker retains its normal size in stathmin-depleted 
cells. Instead, increased microtubule nucleation could spread AURKA beyond the 
centrosome.  Depletion of stathmin not only leads to increased microtubule stability but 
also increased nucleation of new microtubules.  AIR1, a C. elegans homolog of AURKA, 
has been shown to localize to the base of nascent microtubules as well as to other 
molecular scaffolds within the centrosome.  Increased nucleation may provide increased 
binding area for AURKA on newly nucleated microtubules, leading to a dilution of total 
AURKA concentration.  To test this model, nucleation could be increased by some other 
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method such as BRCA1 inhibition, as BRCA1 directly inhibits centrosomal microtubule 
nucleation (Sankaran 2007). Similarly, overexpression of EB1, a microtubule plus tip 
binding protein, may also increase nucleation by conferring increased microtubule 
stability (Holzbaur 2003).  If this model is correct, increased nucleation by any means 
should also result in a wider distribution of AURKA as well as decreased AURKA 
activation.  Similarly, it would also be expected that decreasing or eliminating nucleation 
such as depolymerizing microtubules would rescue AURKA activation.  However, we 
found that, in the absence of microtubules, AURKA is unable to localize at centrosomes 
and remains inactive (Silva and Cassimeris 2013).  This suggests that AURKA requires 
MT for centrosome recruitment but that there must be some normal density of 
microtubules to facilitate both AURKA recruitment and proper centrosomal 
concentration.   
 
Caspase 8 Activation 
 Death ligand independent 
 Stathmin depletion or partial inhibition of AurA and PLK1 at mitotic entry 
decreases cell viability due to stochastic caspase 8 activation and apoptosis (Chapter 3).  
It is possible that cell death occurs in a ligand independent mechanism.  There are 
precedents for caspase 8 induced death in the absence of death receptor ligand binding 
such as from genotoxic stress or loss of caspase 8 inhibitors (Tenev 2011, Day 2008). 
Under certain conditions a caspase-activating platform composed of RIP1/FADD/caspase 
8, called a ripoptosome, assembles spontaneously, independent of ligand signaling 
(Tenev 2011).  Ripoptosome activation is accompanied by NFκB mediated production of 
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autocrine TNF and depletion of cIAPs (cellular inhibitors of apoptotic proteins) followed 
by caspase 8-dependent death (Tenev 2011).   
 Since we observed robust NFκB activation following stathmin depletion, 
suggesting that the cell death observed in the current study is apoptosome dependent.  To 
test if NFκB is mediating autocrine TNF signaling, further experiments might include 
assaying levels of TNFα in media of stathmin-depleted cells or clustering of TNFα 
receptors in the plasma membrane.  Conversely, a complementary approach is to test 
whether NFκB prevents cell death. To test the role of NFκB activation in stathmin 
depletion triggered cell death, we can express dominant negative IκB, cellular inhibitor of 
NFκB, and look for rescue of cell viability.   
 The role NFκB signaling is not fully understood and can result in contradictory 
outcomes, promoting either survival or cell death depending on stimuli and circumstances 
(Fan 2002).   It is possible that NFκB signaling in stathmin-depleted cells promotes 
survival but in a p53 dependent fashion.  NFκB has been shown to upregulate cFLIP to 
inhibit full caspase 8 activity and cell death (Kreuz 2001). However, both the protein and 
mRNA of cFLIP is short lived. Upon treatment with cyclohexamide (a protein synthesis 
inhibitor) or Actinomycin D (RNA synthesis inhibitor) cFLIP levels become nearly 
undetectable after 1 hour treatment and cells are sensitized to TNF stimulated death 
(Fulda 2000).  This suggests that cells are particularly sensitive to cFLIP levels and any 
small changes can produce significant shifts in cell programming. 
 It has been suggested that p53 also positively regulates cFLIP levels via 
transcription and protein stability (Bartke 2001).  Therefore in the absence of p53, despite 
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NFκB upregulated transcription, cFLIP levels may still be decreased. In order to fully 
understand how p53 regulates cFLIP level, we should measure changes in cFLIP mRNA 
with or without stathmin and/or p53.  If mRNA is unchanged by p53 status, it would 
suggest cFLIP protein level is altered by decreased protein stability.  In p53 deficient 
cells, inhibiting protein degradation might restore cFLIP level and rescue the death 
phenotype.  
 In the absence of death ligand-signaling, caspase 8 activation may result solely 
from decreased cFLIP level.  For example, cFLIP knockdown in MCF-7 breast cancer 
cells was shown to be sufficient to induce caspase 8 activation and cell death (Day 2008).  
cFLIP acts as a decoy receptor for caspase 8 and loss of cFLIP increases the likelihood of 
caspase 8 homodimerization and activation.  If this model is correct, immunoprecipitation 
of caspase 8 in p53 deficient cells should show increased association of caspase 8 
homodimers with death inducing signaling complex, DISC components.  Caspase 8 
homodimerization coupled with loss of protective phosphorylation at Serine 387, as seen 
with decreased CDK1 activity, may be sufficient to allow full caspase 8 proteolysis in the 
absence of cFLIP inhibition.  
 
Death Ligand Dependent  
It is possible that caspase 8 activation in stathmin-depleted or CDK1 inhibited cells is 
triggered by autocrine or paracrine release of a death ligand.  Preliminary tests exposing 
naïve cells to conditioned media from stathmin-depleted cells failed to increase cell death 
(Silva and Cassimeris unpublished). This result does not exclude paracrine signaling 
since such signals are likely to be transient and ligands are likely bound to their 
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respective receptors shortly after secretion. It is possible that the resulting extracellular 
concentrations of death ligand are insufficient to induce death in naïve cells. More 
detailed examination of conditioned media, such as by Liquid Chromatography-Mass 
Spectrometry or 2-Dimensional Nuclear Magnetic Resonance may reveal differences in 
cytokine or other death ligand levels.  
 Death receptors only cluster upon ligand binding.  Examination via 
immunofluorescence for coupling of various death receptors such as TNFR, FasR and 
TRAILR could provide evidence for paracrine or autocrine signaling that is not 
detectable with conditioned media experiments.  Given high NFkB activation, signal 
transduction through TNF receptor is likely.  For example, under certain stimuli, cIAPs 
are recruited to ligand-boundTNF receptor clusters initiating signal cascades that result in 
NFκB activation and MAPK signaling which both increase survival.  Interestingly, we 
have observed both increased activation of NFkB and ERK with stathmin depletion.  It is 
possible that an external signal activates a TNF mediated survival signal that is inhibited 
by some other effect of stathmin or p53 loss, such as decreased cFLIP levels.   
 
Conclusions  
Work described in this dissertation outlines a previously unknown mechanism regulating 
mitotic entry timing via both stathmin and microtubules.  Timely activation of AURKA 
and PLK1 requires both spatial and temporal control that is organized in part by changes 
in microtubule stability that occur at the G2/M transition.  Mitotic cells depend on active 
anti-apoptotic signaling, conferred in part by CDK1 activity.  Delaying mitotic onset by 
slowing activation kinetics of CDK1, such as by stathmin depletion, increases 
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vulnerability to cell death after division.  In cells without functional p53 slowing mitotic 
entry, shifts the balance of apoptotic signaling to increase the odds of cell death and 
represents a potent and selective strategy for treating the majority of cancer cell types. 
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